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ABSTRACT 
Exercise-induced bronchoconstriction (EIB) occurs in the majority of asthmatics following 
vigorous exercise. EIB is caused by a loss of water from the airways creating a hyperosmolar 
environment in the tissue that in turn triggers the release of bronchoconstrictive mediators. 
These bronchoconstrictive mediators, including histamine, cysteinyl leukotrienes (CysLTs) 
and prostaglandins, act at their respective receptors on the airway smooth muscle to induce 
bronchoconstriction. Because the mechanism of EIB involves drying of the airways, 
provocations mimicking this drying, such as eucapnic voluntary hyperpnea (EVH) and 
mannitol inhalation can be used to study EIB. With repeated challenge, a smaller response is 
observed following the second challenge and this decreased responsiveness is called 
refractoriness. Defining the mechanism of refractoriness may lead to new treatments for 
asthma.  
     In this thesis a range of airway challenges were performed to study the urinary excretion 
of mediators released in the lung following EIB and the effect of different interventions. 
Furthermore, urinary mediator excretion during refractoriness was also studied.  
     For the first time we demonstrated urinary excretion of CysLT and Prostaglandin D2 
metabolites after EVH. Mediator release was no different in subjects who did not experience 
bronchoconstriction following EVH compared to those who did react with 
bronchoconstriction. This indicates that a necessity of EIB is for the airways to be sensitive to 
the mediators released. Pre-treatment with the mast cell stabilising drug sodium cromoglycate 
(SCG) inhibited the airway response to EVH, and the inhibition was accompanied by a 
decreased release of mediators into the urine. The same effects were observed following pre-
treatment with a single high dose of inhaled corticosteroid (ICS). Pre-treatment with fish oil, 
rich in omega-3 fatty acids, had no effect on the basal excretion of urinary mediators, or 
airway responsiveness to mannitol challenge.  
     We also report the novel finding of refractoriness following repeated mannitol challenge. 
Mast cell mediators were excreted into the urine to the same extent after both the first 
challenge and the repeated challenge 90 min later. Also, those that were most refractory 
displayed the highest mediator release. This contradicts depletion of mediator release at the 
time of the second challenge as being the mechanism of refractoriness. These findings were 
then replicated by repeated EVH challenge. We also demonstrate for the first time an 
extended spectrum of urinary mediators excreted following EVH. Increased levels of the 
bronchoprotective mediators PGE2 and PGI2 were seen, which supports the release of 
protective prostaglandins as being a mechanism of refractoriness.  
     In summary, this thesis provides evidence that the mechanism of refractoriness does not 
involve mediator depletion. Rather, it indicates that there is a decreased sensitivity at the level 
of the airway smooth muscle to the mediators released. The induction of this decreased 
sensitivity may include the release of PGE2 and PGI2, which are likely to mediate protective 
responses.  
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1 INTRODUCTION 
Asthma is a common disease occurring in about 10% of the population worldwide. It is a 
disease of the airways characterised by a variable degree of airway obstruction, airway 
inflammation and airway hyperresponsiveness. The most common symptoms of asthma are 
wheezing, cough, shortness of breath and chest tightness. Even though the disease was first 
described centuries ago, the pathogenesis is still not fully understood, and lack of treatment 
options remain a problem for many patients with asthma.  
     An attack of asthma can be triggered by a wide range of different stimuli ranging from 
common cold or other respiratory tract infections to environmental factors such as allergens 
or exposure to cold dry air. The association between exercise and asthma is known since long 
ago and was first described by Areatus in the first century. Areatus stated “if from running, 
gymnastics exercise or any other work the breathing becomes difficult, it is called asthma” 
(Adams 1856). More recently, studies have shown that the majority of untreated asthmatics 
will experience bronchoconstriction after exercise (Anderson et al. 1975; Godfrey et al. 1991; 
Cabral et al. 1999). The prevalence of this effect in patients with asthma, receiving treatment 
with inhaled corticosteroids, is about 50% (Waalkens et al. 1993; Anderson and Daviskas 
2000; Weiler et al. 2005). Bronchoconstriction upon exercise confirms a diagnosis of asthma 
and an inhibition of the bronchoconstrictor response by a drug is a recognised indication for 
treatment (FDA Guidance for Industry, http://www.fda.gov./cder/guidance)   
     Interestingly, when the exercise challenge is repeated within 2-4 h, about 50% of 
asthmatics will demonstrate a bronchoconstrictor response that is less than half of that seen 
after the initial challenge (Anderson et al. 1979; Schoeffel et al. 1980). This decreased 
responsiveness to challenge is called refractoriness and its duration is usually called the 
refractory period.  
     The mechanism underlying refractoriness has been studied since it was first discovered, 
however it remains largely unclear. Identification of this physiological protective mechanism 
is important since it may lead to the discovery of new targets for treatment, and ultimately aid 
the development of new drugs to treat asthma. 
     The aim of my doctoral studies was to further elucidate the mechanisms of refractoriness 
and better understand mast cell mediator release in exercise-induced bronchoconstriction 
(EIB). We found evidence to suggest that refractoriness is not caused by depletion of 
bronchoconstrictive mediators, which has previously been a dominating theory. We also 
demonstrated for the first time that release of the bronchoprotective mediators PGE2 and PGI2 
could play a role in the development of refractoriness.   
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2 AIMS OF THE THESIS 
The overall objective of the project was to define the mechanisms that explain why an 
episode of exercise-induced bronchoconstriction (EIB) is followed by refractoriness, i.e. a 
reduced response to subsequent challenges. The identification of endogenous protective 
factors may establish new targets for diagnosis, treatment and prevention of asthma.   
 
The project included a series of different exercise challenge studies in subjects with asthma.  
The effects of the challenges and specific interventions on airway function and release of 
bioactive mediators was used to test the following hypotheses: 
1. Refractoriness occurs after mannitol challenge.  
2. EIB following eucapnic voluntary hyperpnea (EVH) is associated with release of 
mast cell mediators into the urine.  
3. Treatments preventing EIB will also affect the mediator release 
a. One high dose of inhaled corticosteroids blunts the EIB following EVH by 
preventing mast cell mediator release 
b. Inhalation of the mast cell stabilising drug sodium cromoglycate prevent EIB 
following EVH by inhibiting mast cell mediator release 
c. Dietary supplementation with omega-3 fatty acids reduces airway 
responsiveness to mannitol challenge by changing the pattern of the mediators 
released 
4. The refractoriness/tolerance phenomenon after EIB occurs at the level of the airway 
bronchial muscle. The corollary of this hypothesis being that release of 
bronchoconstrictive mediators remains unaltered during the refractoriness/tolerance. 
5. Endogenous molecules produced in response to the initial bronchoconstrictive 
episode, determines the degree of refractoriness/tolerance. 
a. Greater release of bronchoconstrictive mediators, such as leukotrienes and 
prostaglandin D2, during the first response, favours increased 
refractoriness/tolerance during subsequent challenges.   
b. Prostaglandin E2 is one key protective factor in the refractoriness/tolerance 
response. 
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3 BACKGROUND 
3.1 ASTHMA 
Asthma has been described by Professor Ann Woolcock as “Airways that constrict too much, 
too often and too easily, resulting in impaired lung physiology and quality of life”. It is a 
common disease affecting about 8-12% of the Swedish population. Asthma can present at 
any time throughout life, even if it is most common during childhood (To et al. 2010). The 
life-time risk of developing asthma is the same as the risk of developing cancer or diabetes, 
however since it often presents early in life, compared to the other diseases, it may cause a 
substantial lifelong burden for the individual (To et al. 2010). The cause of asthma is largely 
unknown; though genetic susceptibility seems to account for one part (Moffatt et al. 2010), 
while infections (Bartlett et al. 2009; Caramori et al. 2012) and environmental factors and 
exposure to allergens may account for another part (Lemanske and Busse 2010). Also, a lack 
of certain microorganisms in the commensal flora has been suggested to affect the immune 
system and trigger the development of deleterious effects that may eventually present as 
asthma (Heederik and von Mutius 2012). However, we still have an incomplete 
understanding of why some develop asthma, whereas others do not. Asthma is thus a 
multifactorial and complex disease, where dysfunction of the airways is however the 
common denominator. 
3.1.1 Asthma phenotypes and why they matter 
Accordingly, asthma is a very heterogeneous disease comprised of patients with a wide range 
of clinical characteristics. Throughout the years several efforts have been made to subgroup 
subjects with asthma, however, there is still no widely accepted definition for what should be 
considered a phenotype and what should not. Classically, asthma was divided into different 
subgroups depending on clinical characteristics; e.g. allergic asthma, exercise-induced 
asthma, fixed airflow limitation, exacerbation prone, obesity related, and eosinophilic asthma 
(Holgate 2011; Wenzel 2013). With the emerging knowledge on genes and molecules, the 
subgrouping has moved from phenotypes to endotypes, instead dividing the disease into 
groups according to molecular mechanisms. Examples of these endotypes could be: Th2 
associated early onset allergic, late onset, IL-5 associated eosinophilic, mast cell associated 
exercise-induced, late onset obese, mild non-CS responsive (Holgate 2011; Wenzel 2013; 
Holgate 2014; Meyers et al. 2014; Fahy 2015). Each suggested endotype is related to specific 
molecular mechanisms; the early onset allergic is for example related to the involvement of 
IL-4/-13 whereas late-onset eosinophilic is more closely related to mediators such as IL-5, 
leukotrienes and eotaxin2.  
     This search for phenotypes and endotypes is more than just an academic exercise, the goal 
of this subgrouping being to predict which treatments are useful for which group of patients 
(Holgate 2013; Holgate 2014; Meyers et al. 2014).  Perhaps the clearest example of the 
usefulness of this subgrouping is the initial failure of anti-IL-5 treatment when given to 
unstratified groups of subjects with asthma. However, when identifying a subgroup of 
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subjects with severe asthma having a high sputum eosinophil count, the medication was 
proven to be very effective (Nair et al. 2009; Castro et al. 2011; Pavord et al. 2012; Bel et al. 
2014a; Bel et al. 2014b; Ortega et al. 2014). As the treatments become more and more 
specific, targeting specific receptors or signalling molecules, we also need to be better at 
defining which patients will benefit from the treatment. This is a major focus of asthma 
research today.  
3.2 AIRWAY CHALLENGES 
Asthma is characterised by variable airway obstruction, airway inflammation and airway 
hyperresponsiveness.  Each of these features can be examined, e.g. the degree of airway 
obstruction can be tested by measuring lung function by spirometry (Miller et al. 2005), and 
the airway inflammation can be assessed by measures such as exhaled nitric oxide (Alving et 
al. 1993). A slightly unique aspect of asthma is that we can provoke attacks of asthma in a 
safe and controlled way in the lab by bronchial challenges (Joos et al. 2003). The bronchial 
provocation is usually classified as “direct” or “indirect”.  
 
Figure 1 Schematic description of the mechanism of action of direct and indirect challenges 
The direct challenges including histamine, methacholine, and leukotriene D4 act at their 
respective receptors on the bronchial smooth muscle, thereby causing bronchoconstriction 
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(Joos et al. 2003). The indirect challenges, includes exercise, allergen, adenosine, hypertonic 
saline and aspirin (in aspirin-intolerant patients). They cause airflow obstruction by inducing 
the release of bronchoconstrictive mediators from inflammatory cells such as the mast cell. 
The direct challenges are very sensitive, however they are not specific for asthma (Hopp et al. 
1984; Cockcroft et al. 1992). The indirect challenges, on the other hand, are less sensitive but 
very specific, meaning that a positive reaction confirms a diagnosis of asthma and the degree 
of responsiveness is closely associated with the degree of airway inflammation (Joos et al. 
2003).  
3.3 MAST CELLS AND LIPID-DERIVED MEDIATORS 
Mast cells are tissue resident inflammatory cells, often located around blood vessels and close 
to body surfaces such as the skin and the lungs. They play an important role in tissue 
homeostasis as well as in host defence against pathogens (Metcalfe et al. 1997). Mast cells 
have been shown to be one of the key disease-triggering cells in asthma, both in acute 
reactions as well as in the chronic changes observed in the airways (Brightling et al. 2002; 
Bradding et al. 2006; Wenzel 2012).  
     Mast cells can be activated by a wide range of stimuli. The classical route is via cross-
linking of immunoglobulin (Ig)E that binds to the Fc receptor on the mast cell, causing the 
mast cell to degranulate. The mast cell releases three classes of mediators: pre-formed (e.g. 
histamine, tryptase), de novo synthesised lipid mediators (e.g. prostanoids and leukotrienes) 
and both preformed and newly synthesised chemokines and cytokines (e.g. TNF-α, and 
interleukins) (Galli et al. 2008; Galli and Tsai 2012). Mast cell can also be activated by other 
stimuli such as hyperosmolarity (Gulliksson et al. 2006), and by drugs, physical stimuli etc. 
(Rothschild 1970; Metcalfe et al. 1997).    
3.3.1 Mast cell-derived lipid mediators 
As stated above, activation of mast cells does not only induce the release of preformed 
mediators but also initiates de novo synthesis and release of lipid-derived substances. Among 
these lipids are the eicosanoids, so called because they contain 20 carbon atoms. The 
eicosanoids are derived from arachidonic acid (AA) which is found in phospholipids in the 
cell membrane. The eicosanoids include prostaglandins (PG), thromboxanes (TX), 
leukotrienes (LT), lipoxins (LX) and a range of hydroxyl and hydroperoxy fatty acids (HETE 
and HPETE). The first group of eicosanoids to be characterised were the prostaglandins, a 
discovery for which the Nobel Prise in Physiology or Medicine in 1982 was granted to 
Bergström, Samuelsson and Vane (Bergström and Samuelsson 1962; Bergström et al. 1964a; 
Bergström et al. 1964b; Piper and Vane 1971; Vane 1971). 
Essential fatty acids are the main elements of the cell membrane in all cells and are called 
essential since they cannot be synthesised in the human body. In humans there are two types 
of essential fatty acids; the ω6-series derived from cis-linoleic acid (LA, 18:2 - meaning it has 
2 double bonds) and the ω3-series derived from α-linoleic acid (ALA, 18:3). LA is converted 
to γ-linoleic acid (GLA) by the enzyme Δ6-desaturase. GLA is then elongated to form 
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dihomo-GLA (DGLA, 20:3ω6 – 3 double bonds with the first located at the 6th carbon atom). 
DGLA is the precursor of the 1-series PGs but it can also be converted to AA by Δ5-
desaturase; AA is the precursor of the 2-series PGs and the 4-series of cysteinyl leukotrienes 
(CysLTs). ALA is converted to eicosapentaenoic acid (EPA, 20:5ω3) by Δ5-6-desaturase; 
EPA is the precursor of the 3-series of PGs and 5-series of CysLTs.  
     Upon activation of the mast cell, the polyunsaturated fatty acid AA (20:4ω6 is liberated 
from the cell membrane by phospholipase A2 (PLA2) via a calcium-dependent mechanism 
(Smith 1989). 
 
 
Figure 2 Overview of the arachidonic acid (AA) metabolism. The arrows indicates enzyme catalysed 
pathways, dashed arrows indicates non-enzymatic pathways.  
COX – cyclooxygenase; 5-LOX – 5-lipoxygenase; 12/15-LOX – 12/15-lipoxygenase; CYP P450 – 
cytochrome P450 monyoxygenase 
3.3.1.1 The cyclooxygenase pathway 
Prostaglandins are formed from arachidonic acid (AA) in a two-step reaction; first AA is 
converted to PGG2 by cyclooxygenase (COX). PGG2 is highly unstable and is further 
metabolised to PGH2 by a peroxidase reaction.  
     PGH2 is then metabolised to the individual prostanoids by specific synthases. Which of the 
prostanoids a cell produces is dependent on the synthases expressed by each individual cell 
(Smith et al. 2000).  
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Figure 3 Overview of prostaglandin (PG) metabolism  
The prostanoids are further metabolised, primarily via a pathway initiated by the oxidation of 
the 15(S)-hydroxyl group by 15-hydroxyprostaglandin dehydrogenase (15-PGDH). This is 
then followed by reduction of the 13 position double bond by 13-15-ketoprostaglandin 
reductase (13-PGR). A separate pathway exists for the oxidation of TXB2 at C-11 by 11-
hydroxythromboxane B2 dehydrogenase (11-TXB2DH) (Westlund et al. 1986). 
     The final degradation products are extensively oxidised before being excreted into the 
urine. The oxidation includes both β- and ω-oxidation, and leads to shortening of the carbon 
chains.  
3.3.1.2 The lipoxygenase pathway 
Following cellular activation, 5-lipoxygenase (5-LOX) is activated by increases in 
intracellular calcium. This activation causes the enzyme to translocate to the nuclear 
membrane where it interacts with 5-LOX activating protein (FLAP) (Miller et al. 1990). 
Following interaction between 5-LOX and FLAP it converts arachidonic acid (AA) to the 
unstable 5-hydroxyperoxyeicosatetraenoic acid (5-HPETE). 5-HPETE can then non-
enzymatically be reduced to 5-HETE, or converted to LTA4 by 5-LOX (Borgeat and 
Samuelsson 1979c; Borgeat and Samuelsson 1979b; Borgeat and Samuelsson 1979a; Borgeat 
and Samuelsson 1979d; Smith 1989).   
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Figure 4 Overview of leukotriene (LT) metabolism 
5-LOX – 5-lipoxygenase; FLAP – 5-LOX activating protein 
In cells containing LTA4 hydrolase (e.g. neutrophils), LTA4 can be converted to LTB4 and in 
cells containing LTC4 synthase (e.g. mast cells and eosinophils), be converted to the first of 
the family of cysteinyl leukotrienes; LTC4 (Welsch et al. 1994; Haeggstrom et al. 2007). In 
human mast cells, an alternative pathway from LTA4 to LTC4 via GSH-s-transferase type 2 
(MGST2) has been shown to exist (Sjostrom et al. 2002). 
     Following exit from the cell, LTC4 is rapidly converted to LTD4 and then to LTE4 by 
peptidases. The majority of the LTE4 is eliminated via the faecal route whereas the other 15-
20% is rapidly filtered in the kidneys and excreted into the urine within 24h (Maltby et al. 
1990).  
3.3.2 Urinary excretion of lipid mediators 
The primary eicosanoids are potent biologically active mediators, but they are troublesome to 
measure since they are very rapidly metabolised and cleared from the circulation 
(Samuelsson et al. 1975). Also, following withdrawal of blood it has been shown that e.g. 
TXB2 can be generated ex vivo (Patrono et al. 1986). Taken together, this often makes the 
measurement of these primary compounds very difficult, and the interpretation of such data 
complicated. Instead, a lot of focus has been put on determination of their respective 
metabolites in body fluids. As an alternative to blood, analysis of excretion products into the 
urine has emerged (Hamberg and Samuelsson 1971).  
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     Accordingly, PGD2 is metabolised by the above mentioned reactions to form 13,14-
dihydro-15-keto-PGD2. This metabolite is then further degraded by oxidation and the final 
metabolites are filtered in the kidneys and released into the urine. The urinary release of 
PGD2 metabolites has been characterised in man by infusing radiolabeled PGD2 into the 
circulation and then collecting urine to measure what is excreted (Liston and Roberts 1985). 
Primary PGD2 was not detectable in urine. Instead, 25 different metabolites were discovered, 
of which 23 showed an F-ring configuration instead of the original D-ring. The earliest 
appearing metabolite was 11β-PGF2α (also commonly known as 9α,11β-PGF2). The 
metabolite 11β-PGF2α is known to have some biological activity such as, bronchoconstriction 
(Beasley et al. 1987; Seibert et al. 1987a; Seibert et al. 1987b). 11β-PGF2α is then further 
metabolised to 2,3-dinor-PGF2α. The most abundant metabolite of PGD2 in the urine is 
tetranor-PGDM.  
Similar metabolic studies to those performed for PGD2, have been carried out to examine the 
urinary excretion of PGE2, PGI2 and TXB2 (Zipser and Martin 1982). Following infusion, 
about 60% of the radioactivity was recovered in urine within 24 h, with most of it recovered 
within 2 h.  
For PGE2 this revealed that only a small proportion of the primary mediator is found in the 
urine (<0.1% when infused in brachial vein and 3.7% when infused in renal artery). The main 
metabolite is tetranor-PGEM. 
PGI2 was recovered as the metabolite 6-keto-PGF1α, and the more abundant 2,3-dinor-6-keto- 
PGF1α.  
TXB2 was only recovered in small amounts, whereas 11-dihydro-TXB2 and 2,3-dinor- TXB2 
are known to be the major urinary metabolites.  
 
Figure 5 Simplified overview of eicosanoid metabolism. Underlined metabolites can be measured in urine 
The use of urinary metabolites to study mechanisms in asthma has become widely accepted, 
especially using 11β-PGF2α and LTE4 (Kumlin et al. 1992; Dahlen and Kumlin 1998; 
O'Sullivan et al. 1998a; O'Sullivan et al. 1998b; O'Sullivan et al. 1999; Brannan et al. 2003; 
Dahlen and Kumlin 2004). The rationale for using urine samples to study the mechanisms 
involved in the reactions that follow an airway challenge, is that upon provocation of the lung 
only, an increase in the urinary excretion of e.g. PGD2 is observed. There is then little doubt 
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that the increase in the urine originates from an increased release in the lung. 
     While the CysLTs can originate from other cells, e.g. eosinophils, PGD2 is known to be 
predominately released by mast cells, and only to a small extent by macrophages (Hsueh 
1979). PGD2 and its metabolites are therefore often used as markers of mast cell activation in 
vivo (Dahlen and Kumlin 1998; O'Sullivan et al. 1999; Dahlen and Kumlin 2004). 
3.4 EXERCISE-INDUCED BRONCHOCONSTRICTION (EIB) 
After Areatus, another early description of EIB was made by Sir John Floyer who in 1717 
stated “all violent exercise makes the asthmatic to breathe short – and if the exercise be 
continued it occasions a fit”. Over the years, EIB has prevented many from performing 
physical activities, as well as made many people avoid any exercise that might provoke 
asthma. This is very unfortunate since the lower the level of fitness; the higher the respiratory 
strain during exercise (Åstrand and Rodahl 1970). Also, with higher strain, the severity of 
EIB is increased, whereas improved fitness is known to decrease the severity of EIB 
(Henriksen and Nielsen 1983; Carlsen et al. 2000).    
3.4.1 How does exercise provoke an attack of asthma? 
With the evidence that increased ventilation is an important factor in EIB, Deal and 
colleagues performed a number of studies focusing on the respiratory heat exchange and 
found a correlation between the airway response and the degree of respiratory heat loss (Deal 
et al. 1979a; Deal et al. 1979b; Deal et al. 1979c). This made the authors suggest that it is the 
cooling of the airways that is responsible for the bronchoconstriction following exercise 
(McFadden et al. 1986). This thermal theory proposes that the increased ventilation during 
exercise causes airway cooling and vasoconstriction, which is followed by rapid rewarming 
and a reactive hyperaemia of the bronchial vasculature at the cessation of exercise. These 
vascular events cause the airways to narrow, and the theory does not encompass bronchial 
smooth muscle or mediator release. The thermal theory initially gained much support, 
however, the documentation of EIB as a result of breathing hot dry air has provided evidence 
that an abnormal cooling of the airways is not a prerequisite for EIB (Anderson et al. 1985).  
     The findings of Anderson and colleagues led to the osmotic theory, which proposes that 
the water loss due to increased ventilation during exercise transiently increases the osmolarity 
of the airway surface (Anderson 1984; Anderson et al. 1985; Anderson et al. 1989; Anderson 
and Daviskas 2000). This event creates a favourable environment for the release of mediators 
such as prostaglandins, leukotrienes and histamine from inflammatory cells and 
neuropeptides from sensory nerves in the airways. 
     It is now recognised that the primary stimulus of EIB is indeed the loss of water from the 
airway surface, caused as a result of the humidification of large volumes of air over a short 
period of time during exercise. The volume of the airway lining fluid is less than 1ml 
throughout the lung and this small volume makes it vulnerable to water loss (Anderson et al. 
1989). In support of this theory, is the finding that EIB can be inhibited or completely 
prevented, by the inhalation of air at a temperature of 37
o
C and a relative humidity of 100% 
(body conditions), during exercise (Anderson et al. 1979; Hahn et al. 1984a). While the 
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vascular effects may play an important role in subfreezing conditions, this effect will become 
less important as the temperature of the inspired air increases. While vascular events will 
amplify the airway narrowing effects of bronchial smooth muscle contraction, it is the release 
of mast cell mediators, and the effects they mediate at their respective receptors, that appear 
to be the most important factor contributing to EIB. 
3.4.2 Pathogenesis of EIB 
Classically, the term exercise-induced asthma (EIA) was used to describe a fall in lung 
function following exercise in subjects with a previous diagnosis of asthma. EIB on the other 
hand, has been used to describe the exercise-induced fall in lung function both in asthmatic 
subjects as well as in subjects without any previous asthma diagnosis. These two groups of 
subjects with EIB may differ slightly when it comes to pathogenesis and treatment, but the 
term EIB is more commonly being used for both groups now. Subjects with asthma and EIB 
most often have an eosinophilic inflammation, and respond well to treatment with 
corticosteroids (Backer et al. 2013). Elite athletes with EIB and no previous history of asthma 
however, seem to have an inflammation that is more often dominated by macrophages and 
neutrophils (Sue-Chu et al. 1999a; Sue-Chu et al. 1999b).   
     EIB is known to be determined by the loss of water from the airway lining fluid, causing 
the release of mast cell mediators which in turn induce bronchoconstriction (Anderson and 
Daviskas 2000). The loss of water from the airway lining fluid may also lead to epithelial 
disruption as indicated by the release of CC16 into urine following EVH, mannitol and 
exercise challenge (Bolger et al. 2011b; Bolger et al. 2011c; Kippelen et al. 2013; Simpson et 
al. 2013). This epithelial damage has been shown to lead to mast cell infiltration in dogs upon 
hyperventilation (Davis et al. 2003). In marathon runners, an influx of neutrophils has been 
seen in conjunction with the epithelial damage (Chimenti et al. 2010). There is also evidence 
to suggest the epithelial damage leads to reduced PGE2 release (Hallstrand et al. 2005a; 
Hallstrand et al. 2005b). In the long term, epithelial damage may also lead to permanent 
changes in the airways. Furthermore, there are indications of an involvement of sensory 
nerves in EIB, although the evidence is not clear (Kippelen and Anderson 2013). 
3.4.3 Mast cell mediators in EIB 
Evidence supporting the release of mast cell mediators following hyperosmolar stimuli comes 
from studies using mannitol, both in vivo and in vitro (Eggleston et al. 1987; Brannan et al. 
2003; Brannan et al. 2006; Gulliksson et al. 2006). The mast cell stabilising agent sodium 
cromoglycate (SCG) also has a protective effect against both exercise and mannitol induced 
bronchoconstriction, supporting an important role for mast cell mediators in the effects of 
both challenges (Tullett et al. 1985; Brannan et al. 2006; Anderson et al. 2010). Further 
support comes from studies of the cysteinyl leukotriene receptor antagonists, which 
significantly attenuate exercise-induced bronchoconstriction (Manning et al. 1990; Dahlen et 
al. 2002) and enhance recovery from mannitol, suggesting that leukotrienes are important in 
both initiating and sustaining the bronchoconstriction (Kemp et al. 1998; Leff et al. 1998). 
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3.4.4 Diagnosis of EIB 
Self-reported symptoms are a poor predictor of the bronchial response to exercise, and also 
the subjective effect of treatment is of little value when diagnosing EIB (Rundell et al. 2001; 
Simpson et al. 2015). This may be problematic in the clinical setting, since a diagnosis of EIB 
in primary care will most often be based on symptoms and the subjective effect of treatment 
alone. Ideally, a diagnosis of EIB requires bronchoprovocations to complement the medical 
history (Anderson and Kippelen 2013). 
     Since EIB depends on the ventilation achieved (Carlsen et al. 2000), it is important that the 
challenge is intense, and not too short. Another important factor to consider is the number of 
airway generations involved in the conditioning of the inspired air; challenges that involve 
recruitment of the small airways are more effective in identifying EIB (Daviskas et al. 1991). 
This may relate to the high density of mast cells in the small airways (Carroll et al. 2002; 
Carroll et al. 2011). Furthermore, there are several factors that can affect the response to 
challenge, including medications and air conditions; all of which need to be taken into 
consideration to optimise the chance of a positive response (Anderson and Kippelen 2013). 
     A diagnosis of EIB should be based on a fall in lung function following airway challenge, 
and many different challenges can be used, such as exercise, mannitol and EVH. The 
different challenge procedures have their pros and cons, but the American Thoracic Society 
(ATS) has published practice guidelines on how to diagnose EIB (Parsons et al. 2013).  
3.4.5 Treatment of EIB 
The treatment of EIB is generally based on the same principals as the treatment of asthma 
(Boulet and O'Byrne 2015). This often means using a β2-agonist for bronchodilation and 
inhaled corticosteroids (ICS) for anti-inflammatory therapy. Guidelines for the treatment of 
asthma suggest that patients with daily symptoms should be treated with ICS, and also that all 
patients should be able to perform unlimited activity or the treatment needs to be intensified 
(Bousquet 2000). For a subject with EIB, however, there are no clear guidelines. It is not 
obvious whether a subject experiencing daily EIB when exercising, but who is symptom free 
at rest, should be considered to have uncontrolled asthma (Backer et al. 2013).  
     Treatment with short-acting β2-agonists (SABAs) or long-acting β2-agonists (LABAs) is 
fundamental. SABAs are often used as monotherapy and have been shown to reduce the fall 
in FEV1 by 70% if taken at least 5 min prior to exercise (Anderson et al. 2006). Also LABAs 
have been shown to be effective in preventing EIB (Richter et al. 2002). However, there is 
evidence that regular use of SABAs or LABAs induces tolerance and a decreased protective 
effect against EIB (Ramage et al. 1994; Simons et al. 1997; Nelson et al. 1998). 
     ICS have been shown to inhibit EIB in asthmatics when given as a regular treatment 
(Weiler et al. 2005; Subbarao et al. 2006). It has also been suggested that a single high dose 
of ICS can be effective in inhibiting EIB (Thio et al. 2001). In guidelines for asthma 
treatment, low-dose ICS treatment is described as add-on to SABAs, but this may be 
insufficient in EIB (Backer et al. 2013). There is evidence of a dose-dependent effect of ICS 
(Subbarao et al. 2006), which suggests that it may be better to increase the dose of ICS rather 
than adding a LABA, which is often suggested in guidelines. The dose of ICS should be 
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titrated according to the response to exercise, and the treatment should give complete 
protection against EIB (Duong et al. 2008).  
     The combination of ICS and LABA is commonly used in the treatment of asthma, and it 
has been shown that treatment with this combination as needed, is as effective as daily 
treatment with ICS (Lazarinis et al. 2014). 
     Antileukotrienes, such as the CysLT1 receptor antagonists montelukast and zafirlukast, 
have been shown to be effective in inhibiting EIB (Manning et al. 1990; Dessanges et al. 
1999; Dahlen et al. 2002; Anderson 2004). Montelukast can be used as monotherapy or in 
combination with the other asthma medications. However, the effect is heterogeneous and not 
of benefit to all subjects.  
     Sodium cromoglycate and other mast cell stabilising agents have been shown to be 
effective in preventing EIB (Tullett et al. 1985; Woolley et al. 1990; Brannan et al. 2006; 
Anderson et al. 2010). These mast cell stabilisers are less potent than the other treatments, 
and also their duration of action is short, which is probably why they are seldom used in the 
treatment of EIB nowadays (Backer et al. 2013). However, they are effective and essentially 
free of side-effects, and may become useful again. 
     In some recent studies, treatment with fish oil that is rich in omega-3 fatty acids has been 
reported to inhibit EIB (Mickleborough et al. 2003; Mickleborough et al. 2006; Tecklenburg-
Lund et al. 2010). These studies are in contrast to previous studies, showing no beneficial 
effects of omega-3 supplement in asthmatic subjects (Arm et al. 1988; Arm et al. 1989b). 
There are currently no official recommendations, suggesting omega-3 for the treatment of 
EIB or asthma in general.  
     Apart from pharmacological interventions, there are also non-pharmacological ways to 
prevent EIB. A short warm-up has been proven effective (Stickland et al. 2012). Also, the use 
of face masks to condition the inspired air is widespread, especially among winter athletes 
(Millqvist et al. 1995). 
3.5 REFRACTORINESS 
McNeill and colleagues were the first to describe refractoriness, namely a decreased airway 
response following repeated exercise challenge (McNeill et al. 1966). It was however, not 
until more than a decade later than Edmunds and colleagues set out to describe refractoriness 
in greater detail (Edmunds et al. 1978). They performed repeated challenges with different 
intervals, and also characterised the effect of work load on the degree of refractoriness. They 
found that the duration of the refractory period varied from 2 to 4 h. The studies also showed 
that the more intense the initial challenge, the more refractory the subjects became to further 
challenge and the shorter the interval between challenges, the higher the degree of 
refractoriness. 
     Refractoriness occurs not only following exercise challenge, but also following other 
indirect challenges such as EVH (Bar-Yishay et al. 1983; Argyros et al. 1995), hypertonic 
saline (Hawksworth et al. 1992), adenosine (Daxun et al. 1989), and ultrasonically nebulised 
distilled water (Mattoli et al. 1987b). All of these indirect challenges are associated with the 
release of mast cell mediators, and the reactions are inhibited by pre-treatment with the mast 
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cell stabilising drug sodium cromoglycate (SCG). The indirect challenges are also thought to 
induce refractoriness via similar pathways (Joos et al. 2003). 
     Further support for similar pathways in the development of refractoriness comes from 
studies of cross-refractoriness between indirect challenges where cross-refractoriness has 
been found between exercise and EVH (Ben-Dov et al. 1983), between hypertonic saline and 
exercise (Belcher et al. 1987), and between exercise and antigen-induced bronchoconstriction 
(Weiler-Ravell and Godfrey 1981). 
     EVH has proven to be a good surrogate for exercise challenge, in that it produces a very 
similar fall in lung function and it leads to the development of a similar degree of 
refractoriness (Rosenthal et al. 1990). Prior to this thesis, it was however not known whether 
refractoriness existed following mannitol challenge. 
3.5.1 Suggested mechanisms 
Since the discovery of refractoriness, there have been speculations as to why it occurs, yet 
little is known about the mechanisms involved. The most common suggestions for the 
mechanism are presented below, for more details see (Larsson et al. 2013). 
3.5.1.1 High levels of catecholamines 
One of the first suggestions to be put forward was that catecholamines released during the 
first challenge provide protection during the second (Larsson et al. 1982). However, in 
studies measuring the levels of epinephrine and norepinephrine, no support for this theory 
could be found (Dosani et al. 1987). In this study, the levels of epinephrine and 
norepinephrine increased both in healthy and asthmatics following exercise challenge, but 
returned to baseline levels before the second challenge was initiated. Of the different airway 
challenges, hypertonic saline is not believed to induce the release of cathecholamines; 
however, this has not been measured locally in the lung. The fact that refractoriness also 
occurs following hypertonic saline, questions the role of catecholamines in the development 
of refractoriness. It should be noted, however, that inhalation of β-receptor antagonists causes 
bronchoconstriction in asthmatics, suggesting that catecholamines play a role in regulating 
airway tone (Okayama et al. 1987). Taken together, it remains to be determined whether 
catecholamines can provide an explanation for the mechanism of refractoriness. 
3.5.1.2 Depletion of mast cell mediators 
As mast cell mediator release became accepted as an integral part of EIB, it was suggested 
that there were not enough mediators released to induce bronchoconstriction following the 
second challenge. This theory was further strengthened by the finding of a relationship 
between the workload during the first challenge and the degree of protection afforded 
(Edmunds et al. 1978). However, the studies that have actually measured levels of the 
mediators suggested to be depleted during the second challenge, have failed to find evidence 
for this (Belcher et al. 1988). This question was therefore further addressed in this thesis. 
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3.5.1.3 Decreased general responsiveness of the airway smooth muscle 
During the time that mediator depletion was a popular theory, the suggestion also emerged 
that the airway smooth muscle itself was less responsive during the second challenge. This 
theory proposes that the airway smooth muscle does not respond normally to the mediators 
released. This theory has been tested in several different studies where the authors have used 
different direct stimuli following various indirect challenges. Following exercise, the 
sensitivity to histamine and methacholine has been reported to be unchanged in refractory 
subjects (Hahn et al. 1984b; Magnussen et al. 1986; Boulet et al. 1987). The same is true for 
methacholine following mannitol challenge (Suh et al. 2011). However, if a histamine 
challenge is performed first, a decreased response to a subsequent exercise challenge is 
observed although interestingly, the opposite was not found (Hamielec et al. 1988).When an 
exercise challenge is performed first, a decreased responsiveness to histamine has been seen 
only after two repeated exercise challenges (Carpentiere et al. 1988). This is in line with the 
finding that it takes multiple histamine challenges before tachyphylaxis is apparent (Schoeffel 
et al. 1980; Boulet et al. 1987). 
     Together these studies do not provide clear evidence that the mechanism of refractoriness 
involves a decreased responsiveness of the airway smooth muscle.   
3.5.1.4 Specific tachyphylaxis to the released mast cell mediators 
Support for the theory that refractoriness is caused by tachyphylaxis to the mediators 
involved in the bronchoconstrictive response, such as histamine, PGs and LTs comes from 
studies of repeated histamine challenge (Schoeffel et al. 1980; Boulet et al. 1987). Also, it has 
been shown that PGF2α induces bronchoconstriction upon inhalation, but when continuing to 
inhale higher doses of PGF2α, there was a return to baseline lung function (Fish et al. 1984). 
Similar effects have been noted previously with repeated PGF2α inhalation in asthmatic 
subjects, but not in healthy controls (Mathe and Hedqvist 1975). It is unclear what the 
mechanism underlying this decreased response is; whether it is the result of a down-
regulation of the receptor for each mediator, or perhaps the release of a protective substance 
preventing the bronchoconstrictive mediator from exerting its action. In the study of Fish et 
al, the protective response was not specific to PGF2α, but rather a decreased response to 
histamine was also seen after PGF2α challenge. This led the authors to suggest the release of a 
protective substance, with reference to in vitro studies, showing the release of the 
bronchoprotective prostaglandins PGE2 and PGI2 in animal models (Piper and Vane 1971). 
     Histamine is only one of the mast cell mediators that has been shown to play a role in EIB, 
and studies of the effect of histamine antagonism have shown that it exerts only a minor role 
in the bronchoconstrictive response following exercise (Dahlen et al. 2002), and EVH 
(Wiebicke et al. 1988). However, this does not rule out the possibility that histamine may 
exert its effects via receptors other than the H1 receptor. In vitro studies have indicated the 
importance of the histamine H2 receptor in the development of tachyphylaxis to repeated 
histamine challenge (Knight et al. 1992). There are also indications that repeated histamine 
challenges induce release of protective prostaglandins as the smooth muscle response was 
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increased in bronchial preparations from patients pre-treated with NSAIDs (Knight et al. 
1995). 
3.5.1.5 Release of protective prostaglandins 
To evaluate the suggestion that refractoriness is caused by the release of a protective 
prostaglandin, several studies of the effect of NSAIDs on the refractory period were 
performed. It was found that pre-treatment with indomethacin blocks the development of 
refractoriness following exercise, EVH, and hypotonic challenge with ultrasonically 
nebulised water (O'Byrne and Jones 1986; Mattoli et al. 1987a; Margolskee et al. 1988; 
Wilson et al. 1994). In these studies, the indomethacin pre-treatment had no effect on the 
response to the initial challenge. The fact that indomethacin abolished refractoriness, strongly 
supports a role for prostaglandins in the protective response. This was then further 
investigated in a comprehensive study by manning et al (Manning et al. 1993). They found 
that there was refractoriness both to repeated LTD4 and exercise challenge, and that there was 
cross-tolerance between the challenges. The refractoriness and the cross-tolerance were 
blocked by pre-treatment with flurbiprofen, suggesting prostaglandins to be involved in the 
protective response. The same authors also tested the effect of histamine H2 receptor 
antagonism on repeated exercise challenge and found no effect on either the first, or the 
second challenge.(Manning et al. 1992)  
     It is not known whether LTD4 inhalation can induce tolerance to a subsequent exercise 
challenge. However, CysLTs have previously been shown to induce the release of PGs in the 
guinea pig in vivo, as well as in vitro.(Piper and Samhoun 1982; Dahlen 1983; Dahlen et al. 
1983; Paruchuri et al. 2008) This suggests that the release of prostaglandins occurs upon 
LTD4 inhalation. Also, evidence for tachyphylaxis has been observed with repeated CysLT 
exposure in isolated guinea pig airways.(Dahlen et al. 1983)  
     The protective prostaglandin has been suggested to be PGE2, which has been shown to 
reduce the duration and severity of bronchoconstriction following exercise.(Melillo et al. 
1994) It has also been shown that PGE2 does not alter the responsiveness to methacholine 
suggesting that it is not working as a functional antagonist.(Pavord et al. 1991; Melillo et al. 
1994). The PGE2 is thought to be released by the airway smooth muscle and the epithelium 
(Delamere et al. 1994; Knight et al. 1995) and its release has also been shown to be 
stimulated by hyperosmolarity (Hjoberg et al. 2000).  However, exactly how PGE2 might 
exert its action was, and has largely remained, unclear. More recently, interesting data has 
emerged indicating that PGE2 may have mast cell stabilising effects preventing the release of 
mediators via the EP2 receptor both in mice (Torres-Atencio et al. 2014), an in man (Säfholm 
et al, J Allergy Clin Immunol in press).   
3.5.2 Humid air and refractoriness      
Studies where subjects inhaled hot humid air during the exercise challenge provided strong 
evidence for the hyperosmolar theory of EIB (Strauss et al. 1978; Hahn et al. 1984a). It 
became clear that breathing hot humid air during the challenge prevented 
bronchoconstriction. Several groups then went on to investigate the effect of humid air on the 
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development of refractoriness. Two studies found that exercise challenge performed at room 
temperature induced a marked bronchoconstriction , when performed 20 min after an initial 
exercise challenge breathing hot humid air, where the initial challenge did not cause any 
bronchoconstriction (Anderson et al. 1979; Hahn et al. 1985). Conversely, refractoriness to 
exercise has been seen when the initial challenge was performed while breathing hot humid 
air (Ben-Dov et al. 1982; Wilson et al. 1990). Wilson and colleagues later showed that this 
protective response is sensitive to NSAIDs (Wilson et al. 1994). The reason why an initial 
non-bronchoconstricting challenge can cause refractoriness to a further challenge remains 
unclear, even though prostaglandins seems to somehow be involved, considering the effect of 
NSAID pre-treatment. However, little is known about how humidity may affect mediator 
release. Previous results suggest that humid air itself can induce a relaxing factor, the effects 
of which last sufficiently long to protect against subsequent exercise challenge (Johnston et 
al. 1992). To further understand the mechanisms involved in the protective effect of hot 
humid air, a study of its effect on EIB-induced mediator excretion was initiated as part of this 
project. 
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4 MATERIAL AND METHODS 
4.1 SUBJECTS AND STUDY DESIGN 
 
Figure 6 Study design Paper I. U-urine sample. 
The aim of Paper I was to test the hypothesis that refractoriness is due to decreased release 
of mast cell mediators following the second challenge. Sixteen asthmatic subjects were 
recruited to Sandra Anderson’s lab in Sydney to perform repeated mannitol challenge. 
Subjects were included if they had a history of asthma, a positive response to mannitol (>15% 
fall in FEV1 following inhalation of ≤635 mg of mannitol) and a spontaneous recovery of 
lung function within 90 min after the challenge. The protocol was approved by the 
institutional Ethics Committee (X05-0068), and the study was carried out under the 
Therapeutic Goods Administration of Australia Clinical Trial Notification scheme (CTN No. 
2005/362). All participants gave their written informed consent before inclusion.  
     On the screening day, a skin prick test was performed. A mannitol challenge was 
performed to confirm a positive response. FEV1 was measured at baseline, 5 min following 
challenge, then at 10 minute intervals for 90 min. If a spontaneous return to within 95% of 
baseline lung function was seen within 90 min the subject was included and called back for 
the study day.  
     On the study day the subjects performed two mannitol inhalation challenges with a 90 min 
interval. The dose that provoked a 15% fall during the first challenge was used during the 
second challenge. Urine samples were collected at baseline and then every 30 min until 180 
min following the first challenge. The sample collected at 90 min before the start of the 
second challenge was used as the second baseline.  
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Figure 7 Study design Paper II. U-urine sample. 
The aim of Paper II was to assess whether a single high dose of beclomethasone 
diproprionate (BDP) could blunt mast cell activation and bronchoconstriction following 
eucapnic voluntary hyperpnea (EVH). Seven endurance-trained athletes with exercise-
induced bronchoconstriction (EIB) and 8 asthmatics were recruited to Sandra Anderson’s lab 
in Sydney to participate in the study. Written informed consent was obtained. The protocol 
was approved by the Central Sydney Area Health Service Ethics Committee (X03-0164). 
Skin prick tests were also performed.  
     To confirm a diagnosis of EIB, the athletes were called into the lab to perform an EVH 
challenge. If a fall in FEV1 of ≥10% from baseline occurred, the subjects were eligible for 
inclusion.  
     On the study day each subject received a placebo aerosol in the morning, 10 min before 
the EVH challenge. In the afternoon 4 h after the EVH challenge the subjects received 1500 
μg BDP (QVAR; 3M Pharmaceuticals, Loughborough, UK). The administration was single-
blinded. A second EVH test was performed 5.5 h after the first. Lung function was measured 
at baseline and 1, 5 and 10 min after challenge, then every 10 min until 90 min after the 
challenge. Urine samples were collected 60 min before each challenge, just before the 
challenge and then every 30 min until 90 min after the challenge.   
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Figure 8 Study design paper III. U-urine sample. 
The aim of Paper III was to clarify the role of mast cell mediators in the airway response to 
exercise in athletes, and also to investigate the effect of the mast cell stabilising drug sodium 
cromoglycate (SCG). Eleven endurance-trained athletes with exercise-induced 
bronchoconstriction (EIB) and 11 without EIB were recruited to Sandra Anderson’s lab in 
Sydney to participate in the study. Written informed consent was obtained. The protocol was 
approved by the Central Sydney Area Health Service Ethics Committee (X03-0164). 
     On the screening day, baseline lung function was measured and a skin prick test carried 
out. An EVH challenge was then performed. The subjects were divided into groups according 
to the fall in FEV1 following EVH; if a fall >10% from baseline lung function occurred the 
subject was classified as EIB+, and if a fall <10% occurred they were classified as EIB-.  
     On the study days, the subjects received either placebo or 40 mg of SCG (8 inhalations of 
Intal Forte; Sanofi Aventis; France) from a pressurised metered-dose inhaler. The 
administration of drugs was randomised and single-blinded. The drug was administered 15 
min before the start of the EVH challenge. Urine samples were collected when subjects 
arrived at the lab, before the start of the EVH challenge and then every 30 min up to 90 min. 
Lung function was recorded at baseline, following administration of the drug and then at 1, 5 
and 10 min after the EVH challenge, and then every 10 min up to 90 min. 
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Figure 9 Study design Paper IV. U-urine sample. 
The aim of Paper IV was to further characterise urinary mediator release during the 
refractory period. The urinary excretion of mediators is delayed compared to the airway 
response, requiring us to determine the optimal interval between challenges to detect 
refractoriness, while still being able to study urinary mediator release. All included subjects 
gave their written informed consent and the study was approved by the local ethics committee 
(Karolinska Institutet regional ethics committee Dnr 03-127, Ethics board Stockholm 
2012/1277-32).  
     To determine the optimal interval between challenges, we performed an initial study 
(study 1) to compare two different intervals between challenges. In this first study 16 
asthmatics were recruited to perform repeated 4 min EVH challenges, either 1 or 3 hours 
apart, in a randomised cross-over design. 
     During screening the subjects underwent a physical examination, skin prick testing, FeNO 
measurement, and spirometry. A 4 min EVH challenge was performed using a slightly 
modified protocol published by Smith et al (Smith et al. 1988). Subjects who met the 
inclusion criteria of a maximum fall in FEV1 ≥10% were included in the study. On the two 
study days, following baseline spirometry and measurement of FeNO, repeated challenges 
with 4 minutes of EVH (challenge I and challenge II) were performed. Urine samples were 
collected 30 minutes before, immediately before the start of the first challenge and then 
hourly until 240 minutes after the first challenge. Lung function was monitored repeatedly.   
     Based upon this initial range-finding study, study 2 was designed.  Now, a 6 minute EVH 
challenge was performed and a fall in FEV1≥15% was a criteria for inclusion. Nine subjects 
were included, but one subject was excluded from analysis because of an asthma 
exacerbation between the screening visit and the study day, leading to 8 subjects being 
eligible for further analysis. The events of the screening day were the same as for study 1 
with the exception of 6 min EVH instead of 4 min EVH.  During the study day the subjects 
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performed repeated challenge with 6 minutes of EVH 3 hours apart. Urine samples were 
collected 30 minutes before, immediately before the start of the first challenge and then every 
hour until 300 minutes after the first challenge. 
 
 
Figure 10 Study design Paper V. U-urine sample. 
The aim of Paper V was to test whether dietary supplementation with omega-3 fatty acids 
could inhibit the bronchial response to mannitol challenge. Eleven asthmatic subjects with 
regular inhaled corticosteroid (ICS) treatment and 12 asthmatic subjects medicating only with 
short acting beta agonists (SABA) as needed, were recruited to Professor Paul O’Byrne’s lab 
in Hamilton, Canada. Written informed consent was obtained. The protocol was approved by 
the ethics review board at St Joseph’s Healthcare, Hamilton, Ontario, Canada (R.P.#06-2750) 
and Health Canada (Approval no. 120532). The trial was registered at ClinicalTrials.gov; No. 
NCT00526357. 
     The study used a randomised, double blind, placebo-controlled, cross-over design. The 
included subjects attended the lab at 4 occasions; at the beginning and at the end of each 
treatment period of 3 weeks. Those on regular ICS-treatment were required to undergo an 
extra visit 2 weeks prior to the first treatment period to confirm that they were responding to 
the mannitol challenge and that their disease was stable.  
     During each visit the subjects completed self-administered questionnaires (Asthma 
Control Questionnaire [ACQ] and Asthma Quality of Life Questionnaire [AQLQ]). Blood 
samples were drawn to assess fasting triglyceride, omega-3 and omega-6 levels. A urine 
sample was collected to assess eicosanoid levels. Then a mannitol challenge was performed 
which was followed by sputum induction.  
     The treatment periods lasted 3 weeks and were separated by a 3 week wash-out period. 
During the treatment periods the subjects were asked to take a daily dose of 10 capsules of 
either matched placebo, containing a mix of omega-6 and omega-9, or 10 capsules of the 
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active treatment, each capsule containing 400 mg of EPA or 200 mg of DHA; (10*40/20EE 
capsules; Ocean Nutrition Canada). 
4.1.1 Ongoing studies:  
 
Figure 11 Study design Humid Air study. U-urine sample. 
In the Humid Air study we want to test the effect of inspired air conditions on urinary 
mediator release following EIB. This study is still ongoing. The protocol was approved by the 
Ethics Review Board at Brunel University, London, U.K. Subjects are being recruited to 
Pascale Kippelen’s lab at Brunel University to perform an exercise challenge test on a cycle 
ergometer; if a fall >15% in FEV1 is observed the subject is eligible for inclusion. 
     During the screening visit and during one of the experimental visits, participants exercise 
whilst breathing air that will be temperate dry (18
o
C and < 8 mg H2O/L). Fully saturated air 
at body temperature (37
o
C and 100%RH) is inhaled during the exercise challenge in the last 
experimental condition. Participants breathe the test air for 4 minutes prior to exercise, for the 
entire duration of the exercise test, and for 2.5 minutes post-exercise. The air is delivered 
through a standard two-way non-rebreathing valve, with a nose clip in place. Participants’ 
heart rate is monitored continuously by short-range radio telemetry using a chest belt. 
Ventilation is monitored by breath-by-breath gas analysis. Oxygen saturation (SpO2) is 
monitored by pulse oximetry using forehead sensors. As a control condition the subjects are 
also to be called back to the lab for a study day during which they sit in the lab while 
monitoring lung function repeatedly. During the study days urine samples are collected twice 
at baseline and then at 45 min intervals following challenge until 180 min. 
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Figure 12 Experimental setup for the Humid Air study  
4.1.2 Isolated human small airways 
To be able to further characterise refractoriness, and try to define the key events involved, we 
set out to develop a new method in which we provoke isolated bronchial segments in an 
organ bath with repeated administration of mannitol solution. This study has been initiated 
and the methodology is still under development.  
     Macroscopically healthy human lung tissue was obtained by consent from patients 
undergoing lobectomy at the thoracic surgery unit at the Karolinska University Hospital, 
Stockholm, Sweden. Before being entered into the study the subjects give their written 
informed consent. The study is approved by the regional ethical review board in Stockholm 
(ref no. 2010/181-31/2).  
 
Figure 13 An organ bath with a bronchial segment mounted between the metal prongs in the centre.  
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     Within 3 hours of surgery, the lung tissue is processed at the Unit for Experimental 
Asthma and Allergy Research where bronchi with an inner diameter ≤1 mm are isolated 
using a dissection microscope. To reduce spontaneous activity the small airway segments 
are placed in culture plate wells containing Dulbecco’s modified Eagle medium and kept 
overnight in a humidified incubator (37 °C at 95% O2 and 5% CO2). The next day 
functional experiments are performed using myographs to record isometric tension 
(ADInstruments Ltd., Hastings, U.K. and Organ Bath Model 700MO, DMT A/S, Aarhus, 
Denmark). The myographs contain Krebs-Ringer PSS and are kept at 37 °C, constantly 
bubbled with carbogen (5% CO2 in O2) to maintain a pH of 7.4. The preparations are then 
allowed to equilibrate for 30 minutes with the buffer changed every 15 minutes, this is then 
followed by a step-wise increase in tension over 60 min to a resting tension of 1.5 mN. The 
protocol is described in more detail by Säfholm et al (J Allerg Clin Immun in press).  
     Following the equilibration period, KCl (60 mM) is added twice with a washout in 
between, to ascertain bronchial reactivity and viability. This is followed by a 60 min 
equilibration, including several washes to allow the segment to return to baseline tension. 
Different agonists and interventions are then administered to the organ bath, to study the 
contractile response.  
4.2 BRONCHIAL CHALLENGES 
As discussed earlier, a feature of asthma that is frequently made use of in research, is the fact 
that an attack of asthma can be induced in the laboratory under controlled conditions. During 
my PhD we have focused on exercise or exercise-mimicking challenges. These exercise-
mimicking challenges include EVH and mannitol which both have proven useful in 
assessments of EIB (Argyros et al. 1996; Brannan et al. 1998; Anderson et al. 2001). 
4.2.1 Mannitol 
Mannitol is a sugar alcohol that was originally isolated from the secretions of a medium-sized 
tree, the flowering ash (fraxinus ornus), and it was called ‘manna’ due to its resemblance to 
the biblical food. Mannitol is listed on the WHO model list of essential medicines as a 
diuretic. In Sweden it is approved for use as a diuretic in the treatment of e.g. oliguric renal 
failure and to reduce intracranial pressure (FASS).  
     Mannitol as an asthma provocation model was first suggested by Anderson and colleagues 
(Anderson et al. 1997). The rationale of using mannitol as a provocation is that it is thought to 
have a similar effect on submucosal osmolarity to that of exercise; upon inhalation a 
hyperosmolar environment favouring mast cell activation is created and a fall in lung function 
similar to that observed following exercise challenge is seen (Anderson et al. 1997; Brannan 
et al. 1998; Brannan et al. 2003; Brannan et al. 2006).   
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Figure 14 Mannitol capsuled and inhaler from the Aridol challenge kit 
     Mannitol was used as the provocation model in Paper I and in Paper V. During the 
challenge subject inhale Mannitol (Aridol, Pharmaxis, Frenchs Forest, NSW, Australia) from 
capsules using a dry powder inhaler (Plastiape, Osnago, Italy). The subject wears a nose-clip 
and is instructed to exhale, followed by a controlled deep inhalation of the powder and 
thereafter hold their breath for 5 s.  The challenge is initiated with an empty capsule and 
FEV1 is measured in duplicate 60 s later. If a fall in FEV1 <10% from baseline is seen the 
challenge is continued with the inhalation of 5 mg mannitol, followed by FEV1 measurements 
in duplicate 60 s later. If the fall in FEV1 is <15% the next dose is doubled to 10 mg. If the 
fall is still <15% from the best FEV1 following the 0 mg capsule baseline values, the dose is 
doubled to 20 mg and then to 40 mg and so on. This is repeated up to a maximum dose of 
160 mg, which is given three times or until the fall in FEV1 is > 15%. The maximum 
cumulative dose given is 635 mg.   
     The dose that elicits a 15% fall in FEV1 (called PD15) can be calculated and is used as an 
indicator of how sensitive a subject is to the challenge; the lower the PD15 value, the more 
responsive the subject is to the challenge.  
4.2.2 Eucapnic voluntary hyperpnea (EVH) 
As it became increasingly apparent that EIB is determined by the degree of ventilation 
achieved, challenges involving hyperventilation instead of exercise were developed. Initially 
the temperature of the air was thought to be an important factor (Phillips et al. 1985). 
However, when it was later shown that temperature was at most a marginal factor (Anderson 
et al. 1979), and the osmotic theory of EIB (Anderson and Daviskas 2000) became more 
popular, more standardised hyperventilation tests were developed (Argyros et al. 1996). 
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     In Paper II and Paper III the protocol used is based on the one originally described by 
Argyros et al.(Argyros et al. 1996) requiring subjects to breathe at a target ventilation of 85% 
of the maximum voluntary ventilation (30*FEV1) for 6 minutes.(Anderson et al. 2001) At 
room temperature a compressed dry gas mixture (~5% CO2, 21% O2, and balance N2) flows 
from a cylinder through a rotameter (Fisher-Rosemount; Brooks Instruments, Hatfield, PA) 
via an open demand valve into a meteorological balloon (300 g, MFG No. 100 MRL; 
Kaysam Corp., Patterson, NJ) via a metal connector with tap (Morgan PKM 90750105) that 
allows simultaneous filling and emptying. The subject inhales the gas via the metal connector 
and breathing tube, via a two-way non-rebreathing valve (Hans Rudolph No. 2700) and a 
mouthpiece. The expired gas passes through a gas meter (American Dry Test Meters; 
American Meter Co., Horsham, PA), and the volume of air expired is then measured.  
     In paper IV a slightly different protocol was used. Hyperpnea with dry, room temperature 
air containing 5% carbon dioxide was performed through  a low-resistance, one-way valve in 
the sitting position (Ailos Asthma Test®, Karlstad, Sweden).(Rosenthal 1984) The target 
ventilation was 35 x FEV1 x 0.75 (L/min) and was maintained for 4 min in study 1 and for 6 
min in study 2. 
4.2.3 Exercise 
In the Humid Air study, which still is ongoing, we use exercise challenge to be able to study 
how the conditions of the inspired air affect urinary mediator release.  
     For this exercise challenge we use a cycle ergometer and the challenge is conducted 
according to the American Thoracic Society (ATS) guidelines for exercise challenge testing 
(Crapo et al. 2000). For this protocol an individual target workload is calculated as follows: 
Watts = (53.76 x measured FEV1) -11.07. The subjects reach this workload after 3 min of 
exercise; the workload will be 60%, 75%, 90% and 100% of the target workload in the first, 
second, third and fourth minute of exercise. The subject then maintains the target workload 
for 5 minutes, making the total challenge time 8 min.    
4.3 LUNG FUNCTION MEASUREMENTS 
To monitor how lung function is affected by the various challenges, we use spirometry. The 
tests have been performed according to American Thoracic Society/European Respiratory 
Society (ATS/ERS) guidelines (Miller et al. 2005) and involves the subject exhaling as fast 
and powerful as possible, following a maximal inspiration whilst connected to a mouthpiece 
and wearing a nose clip. In this manoeuvre we can record lung volume (forced vital capacity, 
FVC) and expiratory flow rates (forced expiratory volume in one second, FEV1, forced 
expiratory flow between 25 and 75% of FVC [FEF25-75] and peak expiratory flow rate 
[PEFR]). 
4.4 URINE SAMPLE COLLECTION AND ANALYSIS 
Urine is the matrix we have used in all of my studies to investigate mediator release. The 
subject was asked to empty his/her bladder into a plastic beaker. The time and volume of the 
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void was noted, and the samples were distributed into smaller plastic tubes, sealed and then 
stored at -20
o
C or -70
o
C until time of analysis. 
4.4.1 Creatinine 
To correct for dilution of the samples, creatinine was measured in all urine samples using a 
colorimetric assay. This method is a slight modification of the Jaffe method (from WHO’s 
Blood Safety and Clinical Technology. Guidelines on Standard Operating Procedures in 
Clinical Chemistry). The method is based on that fact that the creatinine present in urine 
directly reacts with alkaline picrate resulting in the formation of a red colour. The intensity of 
the colour is then measured using a 505nm/green filter. A second absorbance reading after 
acidification with 30% acetic acid corrects for non-specific chromogens in the samples. 
4.4.2 Enzyme immunoassay (EIA) 
Enzyme immunoassay (EIA) was used in all studies to measure the urinary release of 
mediators. Commercially available kits were bought from Cayman Chemicals (Ann Arbor, 
Mi, USA). Urine samples were analysed un-extracted. The assays are based on the 
competition between free eicosanoid and acetylcholinesterase-linked eicosanoid for limited 
specific antiserum binding sites. The eicosanoid-antiserum-complex binds to IgG antibodies 
attached to the bottom of the well. The plate is then washed and Ellman’s reagent added. In 
wells where a large proportion of the eicosanoid is acetylcholinesterase-linked there is a 
stronger colour shift. This is because the acetylcholinesterase cleaves the acetylthiocholine 
component of Ellman’s to give free thiocholine. Thiocholine then reacts with 5-thio-2-
nitrobenzoic acid, a second component of Ellman’s, which gives a distinct yellow colour. The 
density of the colour is determined spectrophotometrically, and is proportional to the amount 
of eicosanoid-acetylcholinesterase bound to the well, which is inversely proportional to the 
amount of free eicosanoid in the original sample. This means the stronger the colour, the less 
eicosanoid present in the urine sample added to that well. 
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Figure 15 Schematic description of the EIA. Reproduced with permission  from Cayman Chemical s 
     To minimise errors in the analysis all samples are serially diluted in 3 different dilutions, 
and all are added to the plate in duplicate; therefore each sample ends up in 6 wells. We then 
discard the dilutions where the wells differ too much (SD >10 or CV >25%) and calculate the 
means of those considered acceptable. 
4.4.3 Mass spectrometry (UPLC-MS/MS) 
With EIA we can only analyse one mediator at a time per sample. Using paper 4 as an 
example where we examined 7 different mediators, this means we had to run 7 different EIA 
kits each time. To be able to simultaneously study several mediators in the same samples we 
participated in the development of a new ultra-performance liquid chromatography-tandem 
mass spectrometry (UPLC-MS/MS) method. Another advantage with the UPLC-MS/MS 
method is that it is very specific and we can therefore be more sure that we are actually 
measuring the intended compound. With EIA there is always a risk of cross-reactivity and 
you may not always actually be measuring what you think you are measuring; this is further 
discussed in the results section. 
     The UPLC-MS/MS analysis was performed in Craig Wheelock’s laboratory at Karolinska 
Institutet. The method is described in greater detail by Balgoma et al (Balgoma et al. 2013). 
During the development of the method it became evident that the concentration of the urine 
sample significantly affected the results Therefore, the method includes a normalisation of the 
extracted urine volume by the ratio of absorbance at 300 nm to an optimised reference 
material. An internal standard for each compound to be measured is added to the sample. 
Following a solid phase extraction (SPE) procedure using HLB Oasis SPE cartridges 
(Waters, Milford, MA), the samples are analysed on the UPLC-MS/MS platform, which 
consists of 4 different methods that collectively measure 30 different eicosanoids and other 
lipid mediators. Prostanoids and isoprostanes are analysed by two methods, one for 
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compounds that undergo tautomerism and one for compounds that do not. A third method is 
applied to measure leukotrienes and a fourth to measure creatinine. The instrument used is a 
liquid chromatograph coupled to mass spectrometer (LC-MS/MS). Separation and 
quantification is performed on a UPLC Acquity-Xevo TQ mass spectrometer system 
(Waters). 
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5 RESULTS AND DISCUSSION 
5.1 DEFINING THE AIRWAY RESPONSE AND LIPID MEDIATOR RELEASE 
FOLLOWING CHALLENGE 
Studying mechanisms of bronchoconstriction due to exercise or exercise-mimicking 
challenges, such as EVH and mannitol, is complicated by the fact that many sampling 
methods can themselves interfere with the physiological response. This is true of induced 
sputum as well as bronhioalveolar lavage (BAL). Urine, on the other hand, is non-invasive 
and does not affect the physiological response. It is therefore attractive as a sampling method, 
however, it may be problematic due to the lag between the peak excretion of mediators in 
urine and the maximum pulmonary response. Therefore, to be able to study mediator release 
during refractoriness we first needed to better characterise the mediator release following 
exercise and exercise-mimicking challenges.   
5.1.1 Mannitol (Paper I) 
Paper I was initiated to study refractoriness following repeated mannitol challenge. The 
subjects performed repeated mannitol challenges, 90 min apart. The results after the first 
challenge confirmed earlier findings from our lab showing that mannitol challenge induces a 
decrease in lung function, which is associated with the release of mast cell-derived lipid 
mediators 11β-PGF2α (previously also called 9α,11β-PGF2α) and LTE4 (Brannan et al. 2003; 
Brannan et al. 2006).   
 
Figure 16 Airway response following mannitol challenge in 16 asthmatics 
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Figure 17 Urinary mediator release following mannitol challenge in 16 asthmatics 
     In the studies by Brannan et al, the release of 11β-PGF2α had returned to baseline within 
90 min, while the release of LTE4 was still elevated. In our study however, the excretion of 
both 11β-PGF2α and LTE4 was still elevated at 90 minutes when the second challenge was 
initiated.  The pattern of release of LTE4, in both our and Brannan’s studies, differed from 
that of 11β-PGF2α in that the peak increase in the urine occurred later. There was however a 
correlation between the peak levels of the two mediators. This suggests that they originate 
from the same source, or that they are released simultaneously from different sources. The 
mast cell is known to be the main source of 11β-PGF2α, which is why this mediator can be 
used as a marker of mast cell activation (Dahlen and Kumlin 2004). CysLTs may originate 
from other inflammatory cells such as eosinophils and alveolar macrophages. However, 
previous findings from our lab confirm that mast cells in vitro release both PGD2 and CysLTs 
upon hyperosmolar stimulation (Gulliksson et al. 2006).  
5.1.2 Eucapnic Voluntary Hyperpnea (EVH) (Paper II + III) 
Study I provided evidence that mannitol causes a very similar reaction to exercise, both 
regarding the airway response, as well as the release of lipid mediators into the urine. Next, 
we wanted to confirm these findings using EVH for which no previous reports of urinary 
mediator release exist. We also wanted to compare the response between healthy subjects, 
asthmatics, healthy elite athletes (EIB-) and elite athletes with bronchoconstriction upon 
exercise (EIB+) to get a better understanding of what determines whether a subject responds 
to EVH challenge.  
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     In Paper II the athletes and untrained subjects with asthma responded similarly to EVH 
challenge with a maximum drop in lung function of about 22 % and 23 % respectively. 
 
Figure 18 Airway response to EVH challenge in 8 subjects with asthma and 7 athletes with EIB 
At baseline, there were no differences in mediator excretion, but following EVH, the 
asthmatics displayed 50% higher levels of both 11β-PGF2α and LTE4. An increase in 11β-
PGF2α levels was seen in both groups; however LTE4 only increased significantly in the 
asthmatics. In the athletes, 11β-PGF2α returned to baseline within 90 minutes, whereas in 
asthmatics the excretion was still elevated. 
 
Figure 19 Urinary mediator release following EVH challenge in 8 subjects with asthma and 7 athletes with EIB 
The mediator excretion was correlated with the maximum fall in lung function. It is not 
known why the asthmatics displayed higher mediator excretion but this might be an effect of 
increased numbers of mast cells in the airways (Brightling et al. 2002; Lai et al. 2014). Also, 
it could be that the mast cells of asthmatics to some extent behave differently than those of 
athletes, either by being more easily triggered to release, or exhibiting a defect in the 
termination of the secretory response. Another possibility is that water transport is somehow 
impaired in asthmatics, leading to the EVH having greater effects on the osmolarity of the 
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airways than what is seen in athletes (Park et al. 2008; Loughlin et al. 2010). Athletes with 
EIB often have sputum neutrophilia in contrast to asthmatics who more often present with 
sputum eosinophilia (Bonsignore et al. 2001). This difference in inflammatory cell 
composition may explain why the athletes did not show increased LTE4, which is known to 
be produced in higher amounts by eosinophils than neutrophils. 
     In Paper III we compared the response to EVH challenge in subjects classified as EIB+ 
(>10% fall in FEV1 at screening) and those classified as EIB-. The post-challenge fall in lung 
function in the EIB+ group was reproduced during the study day, whereas no significant fall 
in lung function was seen in the EIB- group. 
 
Figure 20 Airway response to EVH in 11 athletes with EIB (EIB+) and 11 athletes without EIB (EIB-) 
For the mediators, the baseline levels of 11β-PGF2α were higher in EIB+, whereas LTE4 was 
found to be lower in this group. An increase of 11β-PGF2α was seen in both groups following 
challenge, with the EIB+ having a higher peak excretion compared to EIB-. LTE4 increased 
in EIB+ but not in EIB-.  
 
Figure 21 Urinary mediator release following EVH in 11 EIB+ and 11 EIB- 
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Similarly to study II, there was an association between the fall in lung function and the 
excretion of 11β-PGF2α, however in this study no such association was found for LTE4. 
     Interestingly, the EIB- subjects also excreted mediators following challenge, however not 
to the same extent as the EIB+. This finding suggests that mediator release is a necessity for 
EIB to occur, however the airways also need to be sensitive to the mediators excreted. This 
finding is in line with studies showing an increased reactivity to methacholine in athletes with 
EIB compared to healthy athletes, confirming EIB+ have more sensitive airways compared to 
EIB- (Anderson and Kippelen 2008).   
5.1.3 Exercise and the effect of conditions of the inspired air  
The studies showing no fall in lung function when performing exercise challenge while 
breathing fully saturated humid air, all support the osmotic hypothesis of EIB (Strauss et al. 
1978; Henriksen et al. 1981; Hahn et al. 1984a; Wilson et al. 1990). The absence of a 
pulmonary response is thought to be a consequence of the fact that there is no mediator 
excretion during the humid conditions, however this has never been confirmed by actual 
measurements. We therefore initiated a study to investigate mediator release following 
exercise, either performed breathing room air or hot, humid air.  
     This study is currently ongoing and preliminary results confirm the earlier finding that no 
fall in lung function is apparent while breathing hot, humid air.  
 
Figure 22 Airway response to exercise challenge during different conditions in 7 asthmatic subjects 
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Figure 23 Maximum fall in lung function following exercise challenge during different conditions in 7 asthmatics 
Interestingly, bronchoconstriction was observed in one subject during the control study day 
when the subjects were just sitting still at the lab. However, comparing the maximal fall 
during each of the study days revealed clear differences; with no fall in FEV1 following 
exercise in humid air, while about a 20% fall was seen following exercise in dry temperate 
air. This is well in line with previous findings (Strauss et al. 1978; Anderson et al. 1979).  
     Regardless of the clarity of the airway data so far, the urinary mediator results have been 
inconclusive. More subjects need to be included before any conclusions can be drawn.  
5.1.4 Summary 
To summarise the initial data on mediator excretion, the pattern of mediator release appeared 
to be very similar in exercise (O'Sullivan et al. 1998b), mannitol and EVH challenges, 
lending strong support to the view they act via the same mechanisms. However, comparing 
the magnitude of the mediator release induced by EVH and mannitol, the latter increased 
release by about 100%, whereas EVH increased the release by about 50%. Also, following 
mannitol, the excretion was increased for a longer period. These differences suggest that 
mannitol is a more powerful and long-lived stimuli compared to EVH. 
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Figure 24 Overview of urinary mediator release in paper I-III 
     Another conclusion that can be drawn is that to elicit bronchoconstriction following 
exercise, mediator excretion needs to take place and the individual needs to be somewhat 
sensitive to the mediators released. However, we still did not have a full understanding of 
how long it takes before the excretion returns to baseline, which of course is of vital 
importance when moving on to study mediator release during the refractory period, i.e. what 
happens to the mediator excretion following a second challenge.   
     Humid air protects against bronchoconstriction following exercise, but it is still unclear 
why this is the case. When patient inclusion has been completed and all urine samples have 
been analysed we will most likely have a better understanding of this.  
5.2 THE EFFECT OF INTERVENTIONS ON LIPID MEDIATOR RELEASE AND 
LUNG FUNCTION 
To further understand the involvement of mediators in the development of EIB we also tested 
the effect of various treatments on the lung function and dynamics of mediator excretion 
following challenge.  
5.2.1 Inhaled corticosteroids (Paper II) 
Chronic treatment with inhaled corticosteroids can inhibit EIB in asthmatics (Weiler et al. 
2005; Subbarao et al. 2006). Also, there is evidence that single high doses of ICS can be 
effective in inhibiting the response to exercise (Thio et al. 2001). In study II we tested the 
effect of hydroflouralkane (HFA) beclomethasone diproprionate (BDP), as this is a potent 
glucocorticosteroid with a small particle size, resulting in a greater peripheral deposition 
(Leach et al. 2002). The peripheral airways are of importance since the recruitment of the 
small airways into the conditioning of the inspired air during exercise is thought to be a 
determinant for the severity of EIB (Anderson and Holzer 2000). Also, the small airways 
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have a high content of mast cells in both healthy and asthmatic subjects (Carroll et al. 2002; 
Andersson et al. 2009). 
     Treatment with one single dose (1500 μg) of BDP significantly inhibited the airway 
response in both groups. In both groups, a small bronchodilatory effect was seen after the 
administration of the drug and before the EVH was initiated. BDP also reduced the post-EVH 
maximal change as well as the AUC1-90 for 11β-PGF2α and LTE4, in both asthmatics and 
athletes. 
 
Figure 25 The effect of 1500 μg compared to placebo, on the airway response to EVH challenge in 8 asthmatic subjects 
and 7 athletes with EIB 
 
Figure 26 The effect of 1500 μg compared to placebo, on the urinary 11β-PGF2α release following EVH in 8 asthmatic 
subjects and 7 athletes with EIB 
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Figure 27 The effect of 1500 μg compared to placebo, on the urinary LTE4 release following EVH in 8 asthmatic 
subjects and 7 athletes with EIB 
What needs to be taken in to account however, is that the baseline level of mediators was 
elevated in the afternoon when the BDP treatment was given; this could partly explain the 
differences seen in mediator excretion between treatments. Nevertheless, since there was a 
clear relationship between the fall in lung function and mediator excretion it can also be 
argued that the treatment lead to a real decrease in mediator excretion. 
     The mechanism of the inhibitory effect of one single high dose of BDP is unclear. The 
effect is too rapid to be explained by genomic effects on nuclear glucocorticoid receptors. 
Previously, a single inhalation of ICS has been shown to have no effect on the response to 
direct challenges such as histamine (Ketchell et al. 2002), whereas a protective effect has 
been observed following indirect challenges such as AMP (Ketchell et al. 2002), hypertonic 
saline (Gibson et al. 2001), exercise (Thio et al. 2001), and allergen (Parameswaran et al. 
2000). Together this suggests that the treatment affects the inflammatory cells via which the 
indirect challenges alter the lung function. However, it is unlikely, and there is no evidence 
that a single dose of ICS will reduce the number of mast cells in the airways or that their 
function is acutely altered (Gibson et al. 2001). There is also evidence that glucocorticoids do 
not directly inhibit the biosynthesis of leukotrienes (Gyllfors et al. 2006). 
     ICS have also been shown to be potent vasoconstrictors (Kumar et al. 2000; Mendes et al. 
2003; Ewing et al. 2010), and these vasoconstrictive properties could have counteracted the 
reactive hyperaemia that follows hyperpnea (McFadden et al. 1986). It should be noted 
however that the reactive hyperaemia is thought to comprise only a minor part of EIB 
(Anderson and Daviskas 2000). Also, it is not clear how long-lasting the vasoconstrictive 
effects of ICS are (Kumar et al. 2000; Mendes et al. 2003). It is therefore unclear whether this 
can explain the protective effect of BDP seen 4 h after inhalation.     
     Taken together, the studies mentioned above suggest that there is some kind of effect on 
mast cells, although not a direct effect on their numbers. It may be that BDP prevents mast 
cell mediator release by changing the fluid balance in the epithelium and thereby preventing 
the creation of a hyperosmolar milieu which is normally observed following EVH. In fact, a 
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rapid effect of ICS has been seen on the anti-secretory response of the airway epithelium 
which would support such a phenomenon (Verriere et al. 2005; Urbach et al. 2006). Another 
plausible mechanism, and perhaps more appealing since it also provides an explanation of the 
protection against AMP, is that BDP inhibits mediator release through a reduction in 
intracellular calcium which has been reported in guinea pigs (Zhou et al. 2008).   
5.2.2 Sodium cromoglycate (Paper III) 
We then went on to study the effects of sodium cromoglycate (SCG) which is thought to 
exert its effects by stabilising mast cells and preventing their mediator release. In our study 40 
mg SCG, administered 10 min prior to EVH challenge, decreased the maximum fall in lung 
function by approximately 50% in the EIB+ group. In the EIB- group, as expected, there was 
no significant fall in lung function on either of the study days. SCG blocked the increase in 
11β-PGF2α in both groups, and blocked the increase in LTE4 in the EIB- group.    
 
Figure 28 The effect of 40 mg SCG compared to placebo on the airway response to EVH in 11 EIB+ and 11 EIB- 
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Figure 29 The effect of 40 mg SCG compared to placebo, on the urinary mediator release following EVH in 8 
asthmatic subjects and 7 athletes with EIB 
     The finding that excretion of 11β-PGF2α was inhibited by SCG is in keeping with earlier 
findings from our lab, studying the effect of SCG on mannitol-induced bronchoconstriction 
(Brannan et al. 2006). In that study, there LTE4 release was observed both during placebo and 
SCG treatment, suggesting that LTE4 originates from inflammatory cells other than the mast 
cell, most likely the eosinophil (Moloney et al. 2003). There is however evidence that SCG 
can also inhibit the activation of eosinophils (Moqbel et al. 1986; Kay et al. 1987). The 
differences in the effects of treatment on the response to challenge may also be explained by 
differences in how powerful a stimulus each of the challenges is. It may be speculated that 
EVH is less powerful than mannitol, thereby exerting a relatively smaller effect on 
eosinophils than mast cells, which is supported by the finding that EVH seems to give a 
smaller and more short-lived increase in mediator release compared to mannitol. 
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Figure 30 Comparison of the urinary mediator release in paper I-IV 
The fact that mannitol seems to induce a more pronounced mediator release might be due to 
the fact that the stimulus of the EVH challenge subsides immediately when the challenge is 
stopped. For mannitol, however, it may take some time before the inhaled mannitol is cleared 
from the airways and is stopped from exerting its osmotic effects. Of course, the studies are 
not directly comparable as they do not include the same individuals; however it is a similar 
group of patients in all of them.  
     Another interesting aspect is that in paper I-III, the challenges were performed in 
Australia, whereas in paper IV they were performed in Sweden. In Australia the prevalence 
of house dust mite allergy is high, and the majority of the included subjects were sensitised. 
This means that the subjects undergo challenge during a period when they are exposed to an 
allergen they are sensitised to. This is very different from the situation in Sweden where 
pollen allergies are most common and we do not include patients during the pollen season. 
This means that the subjects are not exposed to an allergen they are sensitised to when 
performing the challenge. The fact that the subjects in Australia may have a more active 
inflammation could explain why the mediator release in paper I was so high. On the other 
hand, the results from the EVH studies were comparable between Australia and Sweden. It 
would be interesting though, to compare EIB and mediator release during and outside the 
pollen season in allergic subjects. 
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5.2.3 Fish oil (Paper V) 
Considering the growing interest and also promising data regarding dietary supplementation 
with omega-3 fatty acids (Mickleborough et al. 2003; Mickleborough et al. 2006; 
Tecklenburg-Lund et al. 2010), we also wanted to examine the effect of pre-treatment with 
omega-3 on the response to mannitol challenge. 
     Three weeks treatment with omega-3 supplements (4.0 g/d eicosapentaenoic acid and 2.0 
g/d docosahexaenoic acid) had no effect, compared to placebo, on the bronchoconstriction 
following mannitol. This was true regardless of whether the participants were treated with 
ICS or not.  
 
Figure 31 The effect of omega-3 supplementation on the airway responsiveness to mannitol challenge in 12 steroid 
naïve asthmatic subjects and 1 asthmatic subjects on regular treatment with ICS 
 
Figure 32 The effect of omega-3 supplementation on the PD15 mannitol in 12 steroid naïve asthmatic subjects and 1 
asthmatic subjects on regular treatment with ICS 
In a subgroup of patients, sputum was also analysed and we did not see any differences in 
eosinophil counts between treatments. Neither did the treatment have any beneficial effects 
on the baseline lung function nor asthma symptom score. The omega-3 did cause a lowering 
of blood triglyceride levels, and as expected, shifts in serum fatty acids and eicosanoid 
metabolites, confirming that the participants were taking their supplements. However, no 
effects were observed on urinary mast cell mediators.  
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     The mechanism thought to explain the suggested positive effects of omega-3, is a 
diversion from the production of bronchoconstricting prostaglandins and leukotrienes 
containing the omega-6-substrate arachidonic acid, towards mediators biosynthesised from 
omega-3 substrates. This of course necessitates that these alternative mediators are less potent 
in causing inflammation and bronchoconstriction. However there is evidence that 5-series 
leukotrienes derived from omega-3 are just as potent as the 4-series that are derived from 
arachidonic acid (Dahlen et al. 1982). The lack of effect of omega-3 may also be explained 
by a failure of omega-3, even in high doses, to alter the substrate flow in tissue residing cells, 
whereas in blood, there are sufficient amounts to alter metabolism. In our study, we saw a 
decrease in serum triglycerides, and it may be that the omega-3 can alter metabolism in blood 
cells and other cells exposed to circulating omega-3, such as endothelial cells and renal 
tubular cells. In support of this, is our finding of increased urinary PGE2 which is thought to 
originate from the kidney (Hamberg and Samuelsson 1971).  
     Our findings support the studies by Arm and colleagues who found no positive effects of 
omega-3 supplements in asthma (Arm et al. 1988). The same authors later saw a small effect 
on the late, but not the early, phase following allergen-induced bronchoconstriction(Arm et 
al. 1989a). Our data is however in conflict with the results of Mickleborough et al (Henriksen 
and Nielsen 1983; Carlsen et al. 2000; Mickleborough et al. 2006), in that we saw no 
beneficial effect of the omega-3 supplement. In the studies by Mickleborough et al they used 
the same type of treatment over the same period of time. The most obvious difference is the 
choice of challenge protocol where we used mannitol as compared to exercise or EVH. The 
studies showing beneficial effects on the response to exercise, were performed until volitional 
exhaustion instead of the recommended standard 8 min protocol in the ATS guidelines 
(Parsons et al. 2013). Another difference is in the study populations, where the subjects in the 
studies by Mickleborough et al, used a high degree of rescue medication with SABA (up to 
10 times daily) without being on ICS, indicating that their symptoms were uncontrolled. This 
might represent a different group of asthmatic subjects compared to the subjects included in 
our study.  
     One weakness in our study is the lack of urine samples following challenge, which 
prevents us from drawing conclusions regarding the effect of changes in mediator release 
caused by the challenge. However, considering no effects at all were seen on the baseline 
excretion along with the absence of effects on the airways, there is little reason to believe 
there to be any effects on the excretion following challenge.  
     In summary, our findings suggest that it is difficult to alter the metabolic profile of tissue 
residing cells such as lung mast cells, and also, that there is most likely still enough 
arachidonic acid available as the preferred substrate for the de novo synthesis of leukotrienes 
and prostaglandins following challenge. Upon stimulation, arachidonic acid is liberated by 
phospholipase A2, which is known to have a preference for phospholipids containing 
arachidonic acid; this in turn may explain why omega-3 has no effect on the response to 
challenges such as mannitol (Leslie 1997).  
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5.3 THE DEVELOPMENT OF REFRACTORINESS FOLLOWING CHALLENGE 
AND ITS RELATION TO RELEASE OF LIPID MEDIATORS 
Following the initial studies focusing on mediator excretion after single challenge, we wanted 
to further study excretion during the refractory period which was also the main purpose of the 
thesis. Exercise-induced bronchoconstriction gained increased interest in the 60’s and 70’s, 
and in the 80’s the mechanisms began to become identified (Anderson and Daviskas 2000). 
Early in this search, refractoriness was found to occur with repeated challenges, and the 
potential to take advantage of this natural protection in the search for new treatments was 
quickly identified. Several suggestions for the mechanism of refractoriness were put forward, 
with the most popular being depletion of mast cell mediators (Edmunds et al. 1978), and the 
release of protective prostaglandins, the latter supported by the finding that NSAIDs abolish 
refractoriness (O'Byrne and Jones 1986; Margolskee et al. 1988).  
5.3.1 Mannitol (Paper I) 
First, we wanted to test whether mannitol-induced bronchoconstriction is followed by a 
period of refractoriness, and secondly we wanted to test whether this refractoriness is 
associated with a decreased release of mast cell mediators.  
     Following the second challenge the maximum fall in lung function was about 50% less 
than the fall following the initial challenge. The degree of protection was individual and 
continuous with a variation from 0 to 88%.   
 
Figure 33 Airway response to repeated mannitol challenge in 16 asthmatics. Arrows indicate time of mannitol 
challenge. 
The release of both 11β-PGF2α and LTE4 was increased both after the first and the second 
challenge. Mediator excretion did not however return to baseline levels before the second 
challenge was initiated which complicates the interpretation to some extent. 
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Figure 34 Urinary mediator release following repeated mannitol challenge in 16 asthmatics 
     Nevertheless, previous studies (Brannan et al. 2003; Brannan et al. 2006) have shown that 
mediator excretion returns to baseline within 90-120 minutes, suggesting that the increase 
following the second challenge is a true increase. These findings are in conflict with mediator 
depletion being the mechanism of refractoriness.  
 
  
Figure 35 Comparison airway response to repeated mannitol challenge in the 6 most refractory and the 6 least 
refractory subjects 
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Figure 36 Comparison of urinary mediator release following repeated mannitol challenge in the 6 most refractory and 
the 6 least refractory subjects 
     Comparing the 6 most refractory with the 6 least refractory subjects revealed a clear 
pattern with the most refractory subjects displaying greatest mediator excretion. This suggests 
that the levels of mediators are important in the development of refractoriness and lead us to 
suggest that the decreased responsiveness occurs at the level of the airway smooth muscle. 
5.3.2 EVH (Paper IV) 
From the results of study I, where excretion was found to be elevated at 90 min, it was 
obvious that we still needed to define the optimal time between challenges in order to study  
mediator release during refractoriness, while making certain not to extend the interval too 
much and thereby missing the refractory period completely. We decided to first compare the 
use of 60 and 180 min intervals between repeated 4 min EVH challenges.  
     In general, the 4 min challenge rendered rather weak responses in the 16 subjects included 
in the study, and several subjects did not reach the maximum fall of  >10% in FEV1 following 
the first challenge. Refractoriness was seen however, yet only accounting for absolute 
differences of a few percent in the maximal fall in lung function. Also, mediator excretion did 
not increase to any great extent following challenge. Nevertheless, the data did not reveal  
evidence of a decreased release following the second challenge. It was clear that a 60 min 
interval is insufficient since this does not allow enough sampling times for the urine. For the 
180 min interval, the mediators had returned to baseline which makes interpretation of 
mediator release following the second challenge more straightforward. 
     Having obtained these results from the first part of the study, we decided to initiate a 
second part using 6 min EVH challenges to optimise the conditions and achieve stronger 
responses, both concerning the airway response and the mediator release. We chose the 180 
min interval between the challenges to be certain that mediators would return to baseline 
before the second challenge. The 6 min challenge did indeed render stronger responses, and 
we found a variable degree of protection in the 8 subjects included. Regarding mediator 
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excretion, the group mean showed an increase in LTE4 but not 11β-PGF2α after the first 
challenge, and vice versa after the second challenge. The patterns displayed by the individual 
graphs, however, showed a strong tendency towards an increase of both mediators following 
both challenges in line with the findings of study I. Presumably the study was slightly 
underpowered to adequately reveal group effects.  
     To get a better understanding of the specific mediators released, we decided to further 
analyse the urine samples using a UPLC-MS/MS panel, enabling us to study a wider range of 
lipid-derived mediators. Of the 30 metabolites included in the panel, we found measurable 
levels of 13. The most abundant mediators in descending order were tetranor-PGEM (~3500 
ng/mmol creatinine), the main isoprostane metabolite 8,12-iPF2α-VI (~500 ng/mmol 
creatinine), tetranor-PGDM  (~200-250 ng/mmol creatinine), and PGF2α (~100 ng/mmol 
creatinine). Metabolites of thromboxane were slightly less abundant, and CysLTs were found 
at the lowest concentrations of all measured compounds. To compare methods, EIAs for a 
range of the mediators found in the UPLC-MS/MS analysis were also used. Comparing EIA 
and UPLC-MS/MS results, the levels detected by EIA were generally higher compared to the 
levels detected by UPLC-MS/MS. There was however a good correlation between the EIA 
and UPLC-MS/MS results. Bland-Altman plots,(Bland and Altman 1986) and correlations 
for the measured mediators are found in paper IV, online supplement figure 2. Graphs 
showing the individual mediators can be found in paper IV, figure 4 and online supplement 
figure 1. 
PGD2 metabolites – the peak excretion of 11β-PGF2α (EIA) compared to baseline did not 
reach significance following challenge I, but there was a significant increase following 
challenge II. The excretion returned to baseline before the start of the second challenge. By 
UPLC-MS/MS, 11β-PGF2α was below the detection limit, however its metabolite 2,3-dinor-
PGF2α was found at similar concentrations to the 11β-PGF2α values indicated by EIA, and an 
increase was observed following both challenges. The EIA results for tetranor-PGDM, a later 
and more abundant metabolite of PGD2, showed increased levels following challenge I, but 
failed to reach significance following challenge I.  Conversely, by UPLC-MS/MS, the 
increase in tetranor-PGDM failed to reach significance following challenge I, but increased 
significantly following challenge II.  
Cysteinyl leukotrienes – there was an increase in LTE4 (EIA) from baseline following 
challenge I, but not following challenge II. The excretion was still elevated before the start of 
the second challenge which may explain why no increase was observed. By UPLC-MS/MS 
most of the subjects displayed increased levels following challenge I, with a strong tendency 
for the whole group although the difference was not statistically different. The levels returned 
to baseline before challenge II, and significantly increased levels were also seen following 
challenge II. 
Thromboxanes, PGF2α and Isoprostanes – TXB2 and its metabolites, the isoprostanes and 
PGF2α failed to display consistent increases, irrespective of whether analysed by EIA or 
UPLC-MS/MS. 
Prostaglandin E2 – The EIA for PGE2 showed increased concentrations following challenge I, 
but not following challenge II. By UPLC-MS/MS the levels of PGE2 were significantly 
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increased following both of the challenges. Tetranor-PGEM increased significantly following 
challenge I, whereas the increase following challenge II failed to reach significance. There 
were no differences in the levels of urinary PGE2 between male and female subjects, whereas 
the levels of PGEM were significantly higher in male subjects. The peak levels of PGE2 or 
PGEM after the first or second challenge did not correlate with the degree of refractoriness.  
Prostacyclin – Using EIA, clear increases in the prostacyclin metabolite 6-keto-PGF1α were 
observed following both challenges. 
 
Figure 37 Overview of mediator release in paper IV. Blue arrows indicate data from UPLC-MS/MS analysis; red 
arrows indicate EIA data. Two way arrows indicate that the data was not consistent for that mediator.  
     Regarding CysLTs and PGD2 metabolites, the current results confirm findings from our 
previous studies, where increased release was observed following exercise and exercise 
mimicking challenges. We also show for the first time that metabolites indicating the release 
of PGE2 and PGI2 were increased  after both challenges. The finding of increased PGE2 and 
PGI2 is interesting since these two mediators are known to be bronchoprotective (Woodward 
et al. 2011). This finding further supports the notion that protective prostaglandins are 
involved in the development of refractoriness, and may explain why pre-treatment with 
NSAIDs blocks the development of refractoriness.  
     We observed increases in both primary PGE2, and its most abundant metabolite tetranor-
PGEM after EVH. This is distinctly different to what has been seen following allergen 
challenge, where no increases in urinary PGE2 or PGEM were seen (Daham et al. 2014). 
Release of PGE2 following EVH, but not allergen challenge may be explained by the 
different mechanisms by which the challenges elicit bronchoconstriction. Both challenges are 
mast cell dependent, but whereas allergen-induced bronchoconstriction is triggered by IgE 
cross-linking, EVH activates mast cells via changes in osmolarity (Anderson and Daviskas 
2000). It is possible that the changes in osmolarity may induce release of PGE2 from other 
cells in the airways, such as the epithelium (Hjoberg et al. 2000; Harrington et al. 2008). This 
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is the first demonstration of increased primary PGE2 following airway challenge, and the 
question arises concerning the source of the PGE2 . From studies of PGE2 metabolism, it is 
known that PGE2 is rapidly metabolised, and urinary PGE2 excretion following the infusion 
of PGE2 was only detectable when given as a renal artery infusion, but not as a brachial vein 
infusion (Zipser and Martin 1982). The current concept is therefore that the kidney itself is 
the exclusive source of urinary PGE2. We think our finding of increased urinary PGE2 could 
be due to the systemic load of PGE2 following a massive release from the airways of which a 
small proportion is excreted in the urine un-metabolised. Another explanation for increased 
urinary PGE2 could also be that the CysLTs induce release of PGs when circulated in the 
renal circulation. Contradicting the latter is the fact that a release of PGE2 should also have 
been observed following allergen challenge, since this challenge caused increases in CysLTs.  
     Another interesting finding were the undetectable levels of 11β-PGF2α following analysis 
by UPLC-MS/MS, whereas the levels of its metabolite 2,3-dinor-PGF2α corresponded well to 
the 11β-PGF2α detectable by EIA. This suggests that what we actually measure with the EIA 
is 2,3-dinor-PGF2α and not 11β-PGF2α.This has previously been noted in work from our 
group (O'Sullivan et al. 1999), though the commonly used term has still been 11β-PGF2α 
since this is the name of the commercially available kit. When testing the cross-reactivity, we 
found that the antibody in the 11β-PGF2α kit recovered 88% of 11β-PGF2α, and 11% of 2,3-
dinor-PGF2α. This indicates a substantial cross-reactivity between the antibody and 2,3-dinor-
PGF2α. Since the two metabolites originate from the same primary mediator, this does not 
have any practical implications for the monitoring of mast cell activation. However, the 
varying terminology may cause confusion and we therefore suggest that, in the future, PGDm 
could be a more useful way to describe these early metabolites of PGD2. 
5.4 ORGAN BATH EXPERIMENTS TO UNDERSTAND MECHANISMS 
Mechanistic studies are often difficult to perform in vivo because certain specific agonists and 
antagonists cannot be administered to humans. As an alternative, we can stimulate human 
airways in an organ bath to study the contractile responses to various stimuli. We therefore 
designed a new model of mannitol stimulation in the organ bath.  
     Jongejan et al. have previously described the effects of hyperosmolar challenge on 
isolated human bronchi (Jongejan et al. 1991). They found that contraction was induced 
with increased osmolarity after the addition of mannitol to the organ bath. These 
contractions were however insensitive to pre-treatment with a histamine antagonist, CysLT 
synthesis inhibitor, the COX-inhibitor indomethacin, as well as the mast cell stabilising 
drug, sodium cromoglycate. Taken together, this would suggest that the 
bronchoconstriction is an effect of osmolarity changes that directly affect the bronchial 
smooth muscle.  
     Other interesting studies of the effects of hyperosmolarity on isolated tissue were 
performed by Hjoberg et al, who in a series of papers describe the effect of hyperosmolarity 
on relaxing factors in the guinea pig trachea (Hjoberg et al. 1999; Hjoberg et al. 2000; 
Hjoberg et al. 2003; Hjoberg et al. 2005). Considering EIB is thought to be caused by 
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changes in osmolarity in the airways upon exercise, and that we believe PGE2 plays a role 
in the development of refractoriness, we wanted to test this further in the human bronchi.  
Adding Mannitol at different concentrations up to 850 mOsm in the bath fluid caused a 
contraction. However this contraction seemed to be caused by a disruption of the membrane 
potential since no further contraction could be elicited. Also, pre-treatment with antagonists 
of PGs, CysLTs and histamine had no effect on the bronchoconstriction, indicating that this 
reaction was not in any way mirroring what we see in vivo following mannitol inhalation.  
     We then went on to test what happened if, following a short exposure to mannitol, we 
changed the media to wash the mannitol away.   
 
Figure 38 Trace of the contractile response in isolated human bronchi in the organ bath. The first peak represents the 
contractile response to potassium chloride (KCL). The contraction then returns to baseline following a wash. 
Mannitol (850 mOsm) is added and a small contraction is seen. Following wash a more powerful contraction is seen; 
this returns to baseline spontaneously after about 20 min. The response to mannitol is the repeatable.  
The observed effect is demonstrated in the traces above. After adding 850 mOsm we saw a 
small contraction. Washing away the mannitol after 10 minutes results in a small relaxation, 
after which a strong contraction is seen. We hypothesised that this second contraction is 
caused by the mediators released from the mast cell, mediators which are bound to their 
respective receptor on the bronchial smooth muscle. When the osmolarity is normalised the 
muscle regains its ability to contract and the mediators can then induce the contraction we 
see. To investigate this theory we then went on to test the effect of different antagonists on 
the second contraction.  
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Figure 39 The effect of interventions on the airway response to mannitol in isolated human bronchi in the organ bath 
Pre-treating the segments with the histamine H1 receptor antagonist mepyramine decreased 
the contraction, and the same was true when pre-treating with the CysLT1 antagonist 
montelukast. Pre-treatment with indomethacin did not decrease the contraction. When pre-
treating with a triple combination, antagonism with mepyramine, montelukast and the TP 
receptor antagonist SQ-29,548, no further was decrease seen, compared to single treatment 
with mepyramine or montelukast.  
     The above described findings are only from one patient, and of course need to be 
replicated before drawing firmer conclusions. However, it is intriguing that we are able to 
induce a response that is similar to EIB in that it is sensitive to histamine and leukotriene 
antagonism. It should be noted, however, that upon inhalation, mannitol affects the 
osmolarity of the submucosa by forcing water across the epithelium; and the smooth muscle 
or the mast cells are most likely never directly exposed to the mannitol itself. In the organ 
bath setup, the epithelium as well as the underlying tissue is directly exposed which of course 
can have great effects.   
     Apart from replicating the findings above, we also need to evaluate the effects of different 
concentrations of mannitol, and different exposure times to fine-tune the system. We then 
want to take it further to try to study refractoriness. From what we have seen this far the 
response is repeatable when the second exposure to mannitol occurs 60 min after the first. 
Perhaps the fact that all the tissue is exposed to mannitol is the explanation for not being able 
to observe refractoriness, and when we wash away the mannitol we may also be washing 
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away important factors involved in the induction of refractoriness. In the future it would be 
interesting to test a setup similar to the one used by Hjoberg et al (Hjoberg et al. 2003), and 
expose only the epithelial surface to the mannitol. 
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6 CONCLUSIONS 
The main conclusions of this thesis are: 
 The mast cell mediators PGD2 and CysLTs are released following exercise, EVH, and 
mannitol challenge. 
 
 The airway response and mediator release is qualitatively similar for the above 
mentioned challenges. Quantitatively, mannitol induced greater mediator release 
compared to EVH. 
 
 The release of mediators occurs in athletes both with and without EIB, indicating that 
airway hyperreactivity towards the released mediators is a key determinant of positive 
EIB. 
 
 SCG and BDP block the airway response following EVH. This was accompanied by a 
decreased release of mast cell mediators indicating these as being a contributing 
mechanism to the decreased airway response after the drugs. 
 
 Treatment with omega-3 fatty acids for 3 weeks had no effect on the airway response 
to mannitol or the urinary release of mast cell mediators. 
 
 The use of EIA is an attractive alternative to UPLC-MS/MS, giving similar 
mechanistic information regarding measurements of CysLTs, metabolites of PGD2, 
PGE2, TXB2 and PGI2. 
 
 Refractoriness after exercise challenge is not caused by a decreased release of mast 
cell mediators following the second challenge. 
 
 Subjects that are more refractory tend to release more mediators, suggesting the 
mechanism of refractoriness involves desensitisation to the released mediators at the 
level of the airway smooth muscle. 
 
 PGE2 and PGI2 are released during the refractory period following EVH, lending 
support for prostaglandins as being of importance to the development of 
refractoriness. 
  
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7 GENERAL DISCUSSION 
Defining mediator release following single challenge 
A prerequisite to be able to define mediator release during the refractory period is to better 
understand the dynamics of mediator release following one single challenge. In our studies, 
as well as in earlier studies (O'Sullivan et al. 1998b; Brannan et al. 2003; Brannan et al. 
2006), we saw increased urinary excretion of CysLTs and PGD2 following different exercise-
type challenges. Urine is attractive in that it is a non-invasive sampling method and does not 
affect the response to the challenge itself. The lag time between the release in the lung and the 
excretion into the urine, may however complicate the interpretation of data. At the time when 
our studies were performed, urine was the only available non-invasive choice considering the 
uncertainty of sampling methods such as exhaled breath condensate (EBC) and saliva (Gaber 
et al. 2006). Invasive methods such as induced sputum are poorly suited for repeated 
measurements following challenge because the collection procedure itself could be 
considered a challenge to the airways.  
     To better characterise the urinary release, to get a better understanding of what happens, 
and when, we compared the use of different challenges, as well as studied the effects of 
different interventions. In this thesis, we describe for the first time the nature of mediator 
release following EVH. Comparing the excretion following challenge, it was obvious that 
mannitol gave a stronger and more long-lived signal regarding mediator release. This may be 
explained by the fact that an EVH challenge lasts for 6 min and thereafter the stimuli ceases 
abruptly. Mannitol on the other hand is given as a step-wise, increasing dose, meaning that 
the challenge itself often takes longer. Also, there is reason to believe that the inhaled 
mannitol takes some time for the lung to eliminate. There is previous data from allergen 
challenges showing that cumulative challenges produce a greater increase in urinary excretion 
of LTE4 than a single-dose challenge (Kumlin and Dahlen 2000).  
     Considering the treatment responses, both the airway response and the release of 
mediators were inhibited by inhalation of SCG, as well as one single high dose of ICS. SCG 
is known to act on mast cells, and probably also on eosinophils, and it is therefore expected 
that we see a decreased response and mediator release. For the high single-dose ICS on the 
other hand, the mechanism of inhibition is less clear, but genomic effects are highly unlikely, 
considering the short time between administration of the drug and the challenge. Since we 
saw decreased mast cell activation, this indicates that mast cells were somehow affected, even 
though little can be said about the mechanisms involved. It may very well be that the ICS 
changes the local milieu of the airways, and thereby simply prevents the osmotic changes that 
otherwise are seen following exercise. Following pre-treatment with omega-3 fatty acids, no 
effect was seen on the bronchial responsiveness to mannitol, or the airway inflammation 
measured by sputum eosinophils. In this study it is unfortunate that no samples were collected 
after the mannitol challenges. However, since there were no effects at all, it is very likely that 
the mediator release after challenge was unaffected.   
     A big step forward in our understanding of the mediators released was the application of a 
recently developed mass-spectrometry method to identify a wider range of eicosanoids and 
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other lipids (Balgoma et al. 2013). It was only possible to apply this method to Paper IV 
within the scope of this thesis. The future analysis of more samples will of course further 
increase our knowledge. This was the first time the release of a wider range of eicosanoids in 
urine was described following EIB. It was striking that even though samples from only 8 
subjects were analysed, the increase in excretion of some of the mediators was very 
pronounced. Another important finding was the, in general, good agreement between EIA 
and UPLS-MS/MS when the methods were compared. Numerically the results were, as 
expected, not always the same, but the pattern of release remained the same. This makes EIA 
an attractive methodological alternative that is more easily available and also less labour 
intensive.  
     Our experiments are designed to assure that each subject is their own control, minimising 
the risk of drawing false conclusions from the data due to variations in the analysis. Given 
that we see some variation in baseline samples, on different days, one single urine sample 
says very little about what is going on. Using creatinine to correct for dilution of the urine 
samples is a generally accepted method and we have used this throughout to be able to 
compare the data. However, we have also started to look into other ways of presenting the 
data; for example calculating excretion per hour instead. This gives slightly different results 
and what should be the method of choice remains to be established. For the time being, we 
continue to normalise in relation to creatinine, one advantage being that this enables 
comparisons with older results.  
     More recently, new non-invasive methods have been developed measuring exhaled 
volatile and non-volatile particles (Fens et al. 2011; Almstrand et al. 2012). There is also a 
new method of bronchosorption where airway lining fluid is absorbed via a device that is 
inserted into the airways through bronchoscopy (Jackson et al. 2014). Urine is still very 
attractive since it is non-invasive and does not affect the challenge itself. The data we have on 
urinary excretion is also robust. However, we do get a reflection of whole body release, and 
even though the vast majority of mediator release occurs in the lung after airway challenge, 
the contribution from the rest of the body remains to be determined. Therefore it is of 
importance to study local release in the airways which may be performed by the methods 
described above. Applying these new techniques could provide a better understanding of how 
local release affects urinary excretion.  
Differences in sensitivity to the released mediators explains EIB 
In paper III, we found that both the EIB+ and the EIB- group demonstrated mediator release 
following EVH. The fact that the mediators released only induced bronchoconstriction in the 
EIB+ subjects raises the question of what differs between these two groups. From previous 
studies, it is known that EIB+ are more sensitive to methacholine challenge, indicating that 
their airways are more hyperreactive and this probably explains why they also respond with 
bronchoconstriction following mediator release. However, it should be noted that we only 
measured CysLT and PGD2 in this study and we don’t know anything about the other 
mediators released. For example, it would be interesting to see if the release of PGE2 differed 
between EIB+ and EIB- subjects. PGE2 inhalation has been shown to protect against allergen, 
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and metabisulphite-induced bronchoconstriction, but no effect has been seen on direct stimuli 
such as methacholine (Pavord et al. 1991; Pavord et al. 1993; Melillo et al. 1994; Gauvreau et 
al. 1999). Also there is evidence suggesting that epithelial injury occurs following exercise or 
exercise mimicking challenges (Bolger et al. 2011a; Bolger et al. 2011c; Kippelen et al. 2013; 
Simpson et al. 2013). Furthermore, it is thought that this injury leads to a decreased release of 
PGE2 (Hallstrand et al. 2005a; Hallstrand et al. 2005b). An alternative explanation of the 
bronchoconstriction in EIB+, but not in EIB-, could therefore involve differences in the 
ability to release PGE2 and protect against the EVH.  
The role of PGE2 in the development of refractoriness 
The inhibitory effect of pre-treatment with NSAIDs on refractoriness is well established 
(O'Byrne and Jones 1986; Mattoli et al. 1987a; Margolskee et al. 1988; Hawksworth et al. 
1992; Manning et al. 1993; Wilson et al. 1994). This strongly suggests that a cyclooxygenase 
product is involved in the development of refractoriness. Of the prostaglandins, PGI2 and 
PGE2 are known to be bronchoprotective, and PGE2 inhalation has been shown to inhibit EIB 
(Melillo et al. 1994). However, no one has previously been able to confirm release of these 
two mediators following EIB. In paper IV we were however able to demonstrate release of 
both PGE2 and PGI2 following EVH for the first time. It remains unclear exactly how the 
protective prostaglandins would exert their actions in EIB. The action of PGE2 has been 
extensively studied and it has been shown that PGE2 exerts its effects via the EP1-4 receptors; 
EP1 and EP3 were thought to mediate bronchoconstriction, whereas it was thought EP2 and 
EP4 caused bronchorelaxation (Woodward et al. 2011). From recent studies however, it seems 
that the situation is more complex. In organ bath experiments, we have established that PGE2 
at lower concentrations relaxes human bronchi, but at higher concentrations causes 
constriction (Säfholm et al, J Allerg Clin Immun in press). The bronchodilation was mediated 
through the EP4 receptor. Moreover, PGE2 inhibited anti-IgE induced bronchoconstriction by 
reducing mast cell mediator release. This effect was shown to be EP2 mediated. 
     These findings are of interest, because they provide a mechanism that could be of 
importance in EIB considering the central role of mast cells. This would suggest that PGE2 
causes refractoriness by inhibiting the release of mast cell mediators, which we however have 
not observed, rather, the release has been the same following both challenges. Also, it is not 
clear how long-lasting this mast cell inhibiting effect is. The urinary excretion of both PGE2 
and PGI2 returned to baseline within 90 minutes, suggesting the release in the lung had 
ceased some time before that. This would seem to make it difficult to explain why 
refractoriness can last as long as 4 hours. Interestingly, in the recent study of PGE2 receptors 
in human bronchi (Säfholm et al), it was found that PGE2 turns on a long-lasting down-
regulation of mast cells.  Irrespective of whether this mast cell inhibition plays a role in 
refractoriness or not, it could also have a vital role in controlling the response to challenge 
itself, as a self-limiting mechanism to stop the reaction from deteriorating. There is evidence 
to suggest that CysLTs themselves can activate mast cells (Paruchuri et al. 2008). This would 
create a self-activating system considering the release of mediators following EIB. 
Mechanisms such as PGE2-induced inhibition of mast cell activation as well as 
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desensitisation of receptors may be vital mechanisms to even survive an exercise challenge. 
Interestingly, considering the “self-activating loop” between CysLTs and mast cells, it is 
known that leukotrienes are important in sustaining EIB (Dahlen et al. 2002; Anderson 2004). 
In general, a lot of attention is often paid to the appearance of a reaction, whereas there is 
little focus is on why it disappears.  
The mystery of humid air 
Another missing link, in the understanding of EIB and refractoriness, is the effect of humid 
air, where a period of tolerance has been noted by some but not by others, when an exercise 
challenge breathing hot humid air is performed before performing an exercise challenge 
breathing room air (Anderson et al. 1979; Ben-Dov et al. 1982; Hahn et al. 1985; Wilson et 
al. 1990). It is interesting that this tolerance after a non-bronchoconstriction challenge is 
sensitive to NSAIDs which suggests similar mechanisms of refractoriness. Generally, it is 
believed that when exercise is performed breathing hot humid air, there is no mediator release 
which would explain the absence of bronchoconstriction. However, it is interesting that if 
humid air is breathed during the recovery phase following challenge, the recovery to baseline 
is much more rapid (Hahn).  This suggests that the humid air itself can induce the release of 
something protective (Johnston et al. 1992). We have initialised a study to compare urinary 
excretion following exercise challenge in either room air or hot humid air, but the data so far 
is inconclusive regarding the mediators released. A further step would then be to examine 
mediator release during the refractory period and the effect of the condition of the inspired 
air.  
A proposal for the mechanism of refractoriness 
In paper I and IV, more emphasis was put into understanding the mechanisms of 
refractoriness. In paper I, we could for the first time demonstrate refractoriness to repeated 
mannitol challenge. This was shortly thereafter replicated by another group (Suh et al. 2011). 
In our study, the release of mediators was increased after both challenges; and the most 
refractory subjects displayed the greatest mediator release. This was then replicated in paper 
IV, where we also saw increased release following the two EVH challenges. From the results 
of Paper I and IV, decreased mediator release seems unlikely as the mechanism, since the 
release of mediators also remained the same after the second challenge. The fact that the most 
refractory in paper I also displayed the highest mediator release, lends support to the notion 
that refractoriness occurs at the level of the airway smooth muscle.  
     Our in vivo studies in intact humans do not permit conclusions about this mechanism to be 
drawn at a molecular level, but the rationale behind this suggestion comes from studies of G-
protein coupled receptors (GPCRs), a family of receptors to which the eicosanoid receptors 
belong. In studies of GPCRs, a very common finding is agonist-promoted desensitisation, 
namely, that with increased or prolonged exposure to an agonist, the receptor of that agonist 
is down-regulated to balance the response (Perry and Lefkowitz 2002). This has been 
extensively studied with the β2-adrenergic receptor which is the target of β2-agonists 
commonly used in asthma treatment (Cazzola et al. 2013). With acute stimulation, this 
desensitisation of the receptor is associated with phosphorylation of the receptor by kinases 
  65 
(McGraw et al. 2003). The receptors are then internalised into the cell by arrestins (Perry and 
Lefkowitz 2002). With more chronic stimuli the expression of the receptor is down-regulated 
and thereby the number of receptors is decreased. In our studies we see an increase in urine 
within 30 minutes, and excretion usually peaks within 60-90 minutes before returning to 
baseline; therefore the dynamics of this response should be considered an acute rather than  
chronic stimulus.  
     From the studies of GPCRs it is obvious that the receptors do not work in isolation but 
rather exhibit extensive cross-talk in a complex manner (McGraw et al. 2007). For example, 
it has been shown that activation of the PGE2 receptor EP1 greatly reduces the 
bronchodilating action of β2-agonists through this cross-talk (McGraw et al. 2006). Similar 
findings exist for the CysLTs (Rovati et al. 2006).   
     In Paper I-IV we found release of CysLTs and PGD, two mediators that are known to be 
involved in EIB. These eicosanoids exert their action via the DP1 and TP receptors, and 
CysLT receptors respectively (Boyce 2007). It is likely that desensitisation occurs similarly to 
what is observed for other GPCR agonists. In vitro LTD4 has been shown to induce 
phosphorylation and internalisation of the CysLT1 receptor (Naik et al. 2005). It is not clear if 
this process of desensitisation occurs at all following exercise challenge. If desensitisation 
does occur, it could also be an explanation of recovery after challenge. Also, it is not clear 
how long-lasting this process is, and if it could explain the development of refractoriness. In 
intestinal epithelium, in vitro, there is evidence that the process of internalisation upon LTD4 
stimulation is very rapid and that the receptors are recycled back to the surface within 15-20 
minutes (Parhamifar et al. 2010). Since refractoriness is also a time-limited response, usually 
not lasting more than 2-3 hours, this internalisation-recycling theory would fit well and also 
explain why the largest degree of refractoriness is seen the closer to the first challenge that 
the second challenge is performed (Edmunds et al. 1978). In our studies, we observe elevated 
urinary excretion for as long as 120 minutes, or even more after challenge (Paper I-IV), 
however, we do not know how long the elevation of mast cell mediator release in the lung 
actually lasts. Also, there is a great variability in the urinary release between different 
subjects which could explain why some are rendered refractory whereas others are not.  
     To summarise the findings of this thesis, I suggest an alternative explanation for the 
development of refractoriness, where PGE2 and/or PGI2 may play a vital role. The fact that 
mediators are released to the same degree after both challenges in papers I and IV suggests 
that the airways are somehow less reactive to the mediators released. Desensitisation is a 
general mechanism seen in GPCR signalling (McGraw et al. 2003), and there is little reason 
to believe this would not also occur in the airways. The effect of NSAID pre-treatment may 
be explained by prostaglandins playing a vital role in the cross-talk between the receptors to 
induce phosphorylation and internalisation. In the absence of prostaglandins, the leukotrienes 
themselves would not be able to induce enough internalisation to decrease the responsiveness 
to further challenge. Whether mediators other than the leukotrienes and prostaglandins are 
involved in this process remains to be established. Also, which receptors are responsible is 
unclear. 
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Figure 40 Desensitisation of the cysteinyl-leukotriene receptor1 as a mechanism of refractoriness.  
With exercise there is release of cysteinyl leukotrienes from mast cells that stimulate the GPCR CysLT1 causing 
contraction of the muscle and exercise-induced bronchoconstriction. The prostaglandins generated during the 
same exercise could, via stimulation of the GPCRs DP1/EP1-4/TP lead to cross talk so that the cyLT1 is 
desensitised though phosphorylation and internalisation. Refractoriness to a second exercise challenge within a 
short period occurs as a result. When the levels of mediators return to baseline values the CysLT1 receptors are 
recycled back to the cell surface and the muscle becomes sensitive to further stimulation. When generation of 
prostaglandins is inhibited by agents such as indomethacin and flurbiprofen then there is limited desensitisation 
of the CysLT1 and therefore limited refractoriness. 
GPCR – G-protein coupled receptor, CysLT1 – cysteinyl leukotriene receptor 1, DP1 – prostaglandin D receptor 1, EP1-4 – 
prostaglandin E receptor 1-4, TP – thromboxane receptor 
Reproduced with permission (Larsson et al. 2013) 
In the search to define the molecular mechanisms involved, we have started to develop a 
method for mannitol challenge in the organ bath. Although we only have preliminary results 
it is a promising method that will hopefully enable us to examine the effect of specific 
agonists and antagonists to more clearly define the role of each mediator. Another interesting 
opportunity is the analysis of histamine in urine (Kolmert et al. 2014) which, in combination 
with the UPLC-MS/MS method, will provide a better understanding of all the mast cell 
mediators involved.  
The overall aim of the project was to define the mechanisms that explain why an episode of 
EIB is followed by refractoriness. Looking back at the results one can say that we made 
several new discoveries which provide the basis for further research on the exact 
mechanisms. The consistent findings of increased mediator release following both challenges, 
and the finding of PGE2 and PGI2 release during refractoriness are two important discoveries. 
Also, the findings will help us to design future studies; perhaps mannitol is a better challenge 
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than EVH if we want a more powerful response when it comes to mediator release. We have 
gained knowledge of the optimal time interval between challenges and this, together with the 
newly developed UPLC-MS/MS platform, has improved our knowledge of what is released 
and when. Considering urinary mediator excretion, I think we have come as far as possible 
when it comes to studying the mechanisms of refractoriness. Apart from measuring local 
mediator release by new methods, another important step in furthering our understanding will 
be to use specific interventions to see how they affect refractoriness. Such interventions can 
be carried out in a clinical setting, but to further elucidate the molecular mechanisms we will 
also have great use of the newly developed model for mannitol challenge of human bronchi 
in the organ bath. 
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Astma är en vanlig luftvägssjukdom som drabbar 1 av 10 i befolkningen. Astma 
kännetecknas av varierande grad av andningssvårigheter, pipande andning, och att 
luftvägarna är hyperreaktiva och inflammerade. Ett astmaanfall kan utlösas av en mängd 
faktorer; allt från kall eller varm luft till allergen och läkemedel. En av de vanligaste 
orsakerna, som kan utlösa astmaanfall är dock ansträngning. När man anstränger sig andas 
man mer, vilket leder till att luftvägarna torkas ut. Denna uttorkning i sin tur leder till att 
mastceller som finns i lungorna frisätter substanser som får luftvägarna att dra ihop sig. 
Exempel på sådana substanser är leukotriener och prostaglandiner. Dessa substanser som 
frisätts i lungorna transporteras med blodet till njurarna och hamnar så småningom i urinen.  
     Något som ses hos astmatiker med ansträngningsutlösta besvär, är att om de först får 
springa för att framkalla ett astmaanfall och sedan återhämta sig, så blir astmaanfallet 
lindrigare om de får springa en andra gång. Att luftvägarna är mindre reaktiva andra gången 
kallas för refraktäritet, och denna effekt kan vara i upp till 4 timmar. Målet med det här 
avhandlingsarbetet var att definiera mekanismerna vid refraktäritet och på så sätt identifiera 
möjliga mål för ny behandling av astma.  
     I den här avhandlingen ingår 5 olika studier där vi provocerat fram astmaanfall genom att 
försökspersoner antingen fått hyperventilera torr luft eller andas in mannitol som är ett pulver 
som torkar ut luftvägarna. Dessa två metoder har tidigare visat sig vara mycket lika 
ansträngning i sättet som de utlöser astmaanfall.  
Både hyperventilering av torr luft och inandning av mannitol utlöste astmaanfall och gav 
ökade nivåer av prostaglandiner och leukotriener i urin. När provokationerna gjordes 
upprepat blev astmaanfallet andra gången lindrigare, d.v.s. de blev refraktära. Refraktäriteten 
sågs trots att det frisattes lika mycket prostaglandiner och leukotriener. Detta skiljer sig från 
det man tidigare trott; att refraktäriteten beror på att det frisätts mindre under andra 
provokationen. Tvärtom var det så att de med högst grad av refraktäritet (störst skillnad 
mellan astmaanfallen efter första, respektive efter andra provokationen) var de som hade de 
högsta nivåerna av prostaglandiner och leukotriener i urinen. 
I en av studierna mätte vi ett bredare spektrum av substanser och fann då att en viss typ av 
prostaglandiner, som anses skydda mot astmaanfall, frisätts efter att försökspersonerna 
hyperventilerade torr luft. Det skulle kunna tyda på att denna typ av prostaglandiner är viktiga 
för utvecklingen av refraktäritet. 
Vi testade även effekten av olika behandlingar, dels på hur kraftigt astmaanfall som utlöses 
av provokationerna, men även hur det påverkar frisättningen av substanser till urinen. 
Inhalationskortison, som är en vanlig medicin vid astma; i en hög dos hindrade det 
astmaanfall och minskade också mängden prostaglandiner och leukotriener i urinen. 
Kromoglikat, som man tror verkar genom att hindra mastcellerna från att frisätta substanser, 
förhindrade även det astmaanfall efter torrloftsprovokation. Ingen ökning av mängden 
prostaglandiner och leukotriener i urinen sågs efter förbehandling med kromoglikat. Slutligen 
testade vi effekten av 3 veckors behandling med fiskleverolja som vissa tror kan ha 
gynnsamma effekter, vi såg däremot ingen som helst effekt av fiskleveroljan. 
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     Sammanfattningsvis tyder våra resultat på att refraktäritet beror på att luftvägarna är 
mindre reaktiva för de substanser som frisätts när försökspersonerna provoceras för andra 
gången. Exakt vad denna minskade känslighet beror på går inte att säga utifrån de nuvarande 
resultaten men detta kommer undersökas vidare. En viss typ av prostaglandiner som kan 
skydda mot astmaanfall verkar ha en viktig roll.  
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